Genetically modified yeast cells and methods of use thereof
Patent Information
- Application Number
- JP2023528982
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-13
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-20
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63 / 113,747, filed November 13, 2020, the entire disclosure of which is incorporated herein by reference in its entirety.
[0002] Government support This invention was made with government support under Award No. 1831242 awarded by the National Science Foundation. The government has certain rights in this invention. [Background technology]
[0003] background Fruity tropical fruit flavors are highly desirable in the fermented beverage market. While fruity-flavored wines, such as Chardonnay and Sauvignon Blanc, account for the majority of wine sales in the United States (Statista (2019), Wine Consumption by Category, United States), the popularity of beer made with fruity flavoring hops has skyrocketed over the past decade (Craft Beer Club (2018), Your Guide to the Most Popular Beer Hops in the USA; Watson (2018), Beer Style Trends). The fruity flavors present in both beer and wine arise from the presence of volatile flavor-acting molecules that impart fruity aromas and tastes when present at concentrations above the human detection threshold. One flavor molecule that imparts fruity tasting notes is the ester ethyl hexanoate. Ethyl hexanoate is an important contributor to the flavor of pineapple, but it is also an essential component of other fruity flavors such as mango, guava, and apple (Reddy et al. Indian J. Microbiol. (2010). 50:183-191; Zheng et al. Int. J. Mol. Sci. (2012). 13:7383-7392; Kaewtathip et al. Int. J. Food Sci. Tech. (2012). 47:985-990; Espino-Diaz et al. Food Technol. Biotechnol. (2016). 54:375). Summary of the Invention
[0004] overview In some aspects, the present disclosure provides genetically modified yeast cells containing a gene encoding an enzyme with alcohol-O-acyltransferase (AAT) activity and a gene encoding an enzyme with fatty acid synthase (FAS2) activity. The enzyme with AAT activity catalyzes the reaction of ethanol with hexanoic acid or hexanoyl-CoA to form the fatty acid ester ethyl hexanoate, which imparts a fruity pineapple flavor to fermented beverages such as beer and wine. Thus, while modified cells with AAT activity may produce ethyl hexanoate during fermentation (thereby imparting such flavor to the resulting fermented beverage), they may also produce hexanoic acid, a pungent fatty acid that can impart an undesirable, cheesy, rancid, or goat-like flavor when present at concentrations above the flavor detection threshold. The enzyme with FAS2 activity functions to elongate fatty acid chains. Thus, modified cells with altered FAS2 activity may also produce short fatty acid chains (e.g., in the form of hexanoyl-CoA) that are precursors for producing ethyl hexanoate. The modified cells described herein further aim to minimize the production of hexanoic acid during fermentation, thereby avoiding the imparting of unpleasant flavors to the resulting fermented beverage. The modified cells of the present disclosure may also contain a third gene encoding an enzyme with hexanoyl-CoA synthetase (HCS) activity. An enzyme with HCS activity catalyzes the formation of hexanoyl-CoA from the substrate hexanoic acid and free coenzyme A (CoA). Thus, by converting hexanoic acid to a precursor for ethyl hexanoate synthesis, modified cells with HCS activity can produce both more ethyl hexanoate and less hexanoic acid during fermentation, imparting more desirable flavors and fewer undesirable flavors to the resulting fermented beverage.The enzymes may be further modified to increase their production of ethyl hexanoate or decrease production of hexanoic acid, and the genes encoding the enzymes may be operably linked to promoters to further increase ethyl hexanoate production or decrease hexanoic acid production.
[0005] In some aspects, the present disclosure provides a genetically modified yeast cell (modified cell) comprising a first gene encoding an enzyme with alcohol-O-acyltransferase (AAT) activity operably linked to a first promoter, and a second gene encoding an enzyme with fatty acid synthase (FAS2) activity operably linked to a second promoter. In some embodiments, the enzyme with AAT activity is derived from Marinobacter hydrocarbonoclasticus, Fragraia x ananassa, Saccharomyces cerevisiae, Neurospora sitophila, Actinidia deliciosa, Actinidia chinensis, Marinobacter aquaeolei, Saccharomycopsis fibuligera, Malus x domestica, Solanum pennellii, or Solanum lycopersicum. In some embodiments, the enzyme with AAT activity comprises a sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NOs: 2-4 or 12-22. In some embodiments, the enzyme having AAT activity does not comprise the sequence of SEQ ID NO: 1. In some embodiments, the enzyme having AAT activity comprises the sequence of SEQ ID NO: 20.
[0006] In some embodiments, the first enzyme having AAT activity comprises at least one substitution mutation at a position corresponding to position A144 and / or A360 of SEQ ID NO: 1. In some embodiments, the substitution mutation at the position corresponding to position 144 of SEQ ID NO: 1 is phenylalanine. In some embodiments, the substitution mutation at the position corresponding to position 360 of SEQ ID NO: 1 is isoleucine.
[0007] In some embodiments, the enzyme with AAT activity comprises at least one substitution mutation at a position corresponding to position A169 and / or A170 of SEQ ID NO: 19. In some embodiments, the substitution mutation at a position corresponding to position 169 of SEQ ID NO: 19 is glycine. In some embodiments, the substitution mutation at a position corresponding to position 170 of SEQ ID NO: 19 is phenylalanine. In some embodiments, the first enzyme with AAT activity comprises a substitution mutation at a position corresponding to position G150 of the wild-type MhWES2 amino acid sequence. In some embodiments, the substitution mutation at a position corresponding to position G150 of the wild-type MhWES2 amino acid sequence is phenylalanine.
[0008] In some embodiments, the enzyme having FAS2 activity is derived from Saccharomyces cerevisiae. In some embodiments, the enzyme having FAS2 activity comprises a sequence having at least 90% sequence identity to the sequence of SEQ ID NO:6. In some embodiments, the enzyme having FAS2 activity does not comprise the sequence of SEQ ID NO:5. In some embodiments, the enzyme having FAS2 activity comprises a substitution mutation at a position corresponding to position 1250 of SEQ ID NO:5. In some embodiments, the substitution mutation at the position corresponding to position 1250 of SEQ ID NO:5 is serine.
[0009] In some embodiments, the modified cell further comprises a third heterologous gene operably linked to a third promoter, wherein the third heterologous gene encodes an enzyme having hexanoyl-CoA synthetase (HCS) activity. In some embodiments, the enzyme having HCS activity is derived from Cannabis sativa. In some embodiments, the enzyme having HCS activity comprises a sequence having at least 90% sequence identity with the sequence of SEQ ID NO:7.
[0010] In some embodiments, the first promoter and / or the second promoter is selected from the group consisting of pHEM13, pSPG1, pPRB1, pQCR10, pPGK1, pOLE1, pERG25, and pHHF2. In some embodiments, the first promoter is pHEM13 and the second promoter is pSPG1. In other embodiments, the first promoter is pHEM13 and the second promoter is pPRB1. In another embodiment, the first promoter is pQCR10 and the second promoter is pPRB1. In another embodiment, the first promoter is pPGK and the second promoter is pPRB1.
[0011] In some embodiments, the third promoter is selected from the group consisting of pHEM13, pSPG1, pPRB1, pQCR10, pPGK1, pOLE1, pERG25, and pHHF2. In some embodiments, the first promoter is pHEM13, the second promoter is pPRB1, and the third promoter is pHEM13. In other embodiments, the first promoter is pQCR10, the second promoter is pPRB1, and the third promoter is pHEM13. In other embodiments, the first promoter is pPGK1, the second promoter is pPRB1, and the third promoter is pERG25.
[0012] In some embodiments, the cells are genetically modified to reduce expression of one or more endogenous AAT enzymes. In some embodiments, the modified cells do not express endogenous EEB1, EHT1, and / or MGL2.
[0013] In some embodiments, the yeast cell is of the genus Saccharomyces. In some embodiments, the yeast cell is of the species Saccharomyces cerevisiae (S. cerevisiae). In some embodiments, the yeast cell is a S. cerevisiae California Ale yeast strain WLP001, EC-1118, Elegance, Red Star Cote des Blancs, or Epernay II. In some embodiments, the yeast cell is of the species Saccharomyces pastorianus (S. pastorianus).
[0014] In some embodiments, the growth rate of the modified cells is not substantially impaired compared to wild-type yeast cells that do not contain the first heterologous gene and the second exogenous gene. In some embodiments, within one month of initiating fermentation, the modified cells ferment an amount of fermentable sugars equivalent to the amount fermented by wild-type yeast cells that do not contain the first heterologous gene and the second exogenous gene. In some embodiments, within one month of initiating fermentation, the modified cells reduce the amount of fermentable sugars in the medium by at least 95%. In some embodiments, the cells contain an endogenous gene encoding an enzyme having FAS2 activity.
[0015] Some aspects of the present disclosure provide methods for producing a fermentation product, comprising contacting the modified cells with a medium containing at least one fermentable sugar, wherein the contacting is performed during at least a first fermentation process to produce the fermentation product. In some embodiments, the at least one fermentable sugar is provided in at least one sugar source. In some embodiments, the fermentable sugar is glucose, fructose, sucrose, maltose, and / or maltotriose.
[0016] In some embodiments, the fermentation product comprises an increased level of at least one desired product compared to a fermentation product produced by an equivalent cell that does not express the first, second, and / or third heterologous genes or an equivalent cell that expresses a wild-type enzyme having AAT activity. In some embodiments, the desired product is ethyl hexanoate.
[0017] In some embodiments, the fermentation product comprises a reduced level of at least one undesired product compared to a fermentation product produced by an equivalent cell that does not express the first heterologous gene, the second exogenous gene, and / or the third heterologous gene, or an equivalent cell that expresses a wild-type enzyme having AAT activity. In some embodiments, the at least one undesired product is hexanoic acid.
[0018] In some embodiments, the fermented product is a fermented beverage, hi some embodiments, the fermented beverage is beer, wine, sparkling wine (champagne), wine cooler, wine spritzer, hard seltzer, sake, mead, kombucha, or apple cider.
[0019] In some embodiments, the sugar source comprises malt, must, fruit juice, honey, rice starch, or a combination thereof. In some embodiments, the fruit juice is obtained from at least one fruit selected from the group consisting of grapes, apples, blueberries, blackberries, raspberries, currants, strawberries, cherries, pears, peaches, nectarines, oranges, pineapples, mangoes, and passion fruit.
[0020] In some embodiments, the sugar source is wort, and the method further comprises producing a medium, wherein producing the medium comprises: (a) contacting a plurality of grains with water; and (b) boiling or steeping the water and grains to produce the wort. In some embodiments, the method further comprises adding at least one hop variety to the wort to produce a hopped wort. In some embodiments, the method further comprises adding at least one hop variety to the medium.
[0021] In some embodiments, the sugar source is fruit must, and the method further comprises producing a medium, wherein producing the medium comprises pressing the plurality of fruits to produce the fruit must, hi some embodiments, the method further comprises removing solid fruit material from the fruit must to produce juice.
[0022] In some embodiments, the method comprises at least one additional fermentation process, hi some embodiments, the method comprises carbonating the fermentation product.
[0023] In some aspects, the present disclosure provides a fermentation product produced, obtained, or obtainable by one of the methods described herein. In some embodiments, the fermentation product contains at least 200 μg / L of ethyl hexanoate. In some embodiments, the fermentation product contains less than 10 mg / L of hexanoic acid.
[0024] Some aspects of the present disclosure provide methods for producing a composition comprising ethanol, the methods comprising contacting the modified cells with a medium comprising at least one fermentable sugar, wherein such contacting is performed during at least a first fermentation process to produce a composition comprising ethanol.
[0025] In some embodiments, at least one fermentable sugar is provided in the at least one sugar source, hi some embodiments, the fermentable sugar is glucose, fructose, sucrose, maltose, and / or maltotriose.
[0026] In some embodiments, the composition comprising ethanol comprises an increased level of at least one desired product compared to a composition comprising ethanol produced by a comparable cell that does not express the first, second, and / or third heterologous gene, or a comparable cell that expresses a wild-type enzyme having AAT activity. In some embodiments, the desired product is ethyl hexanoate.
[0027] In some embodiments, the composition comprising ethanol comprises a reduced level of at least one undesired product compared to a composition comprising ethanol produced by a comparable cell that does not express the first heterologous gene, the second exogenous gene, and / or the third heterologous gene, or a comparable cell that expresses a wild-type enzyme having AAT activity. In some embodiments, the at least one undesired product is hexanoic acid.
[0028] In some embodiments, the composition comprising ethanol is a fermented beverage, hi some embodiments, the fermented beverage is beer, wine, sparkling wine (champagne), wine cooler, wine spritzer, hard seltzer, sake, mead, kombucha, or apple juice.
[0029] In some embodiments, the sugar source comprises malt, must, fruit juice, honey, rice starch, or a combination thereof. In some embodiments, the fruit juice is obtained from at least one fruit selected from the group consisting of grapes, apples, blueberries, blackberries, raspberries, currants, strawberries, cherries, pears, peaches, nectarines, oranges, pineapples, mangoes, and passion fruit.
[0030] In some embodiments, the sugar source is wort, and the method further comprises producing a medium, wherein producing the medium comprises: (a) contacting a plurality of grains with water; and (b) boiling or steeping the water and grains to produce the wort. In some embodiments, the method further comprises adding at least one hop variety to the wort to produce a hopped wort. In some embodiments, the method further comprises adding at least one hop variety to the medium.
[0031] In some embodiments, the sugar source is fruit must, and the method further comprises producing a medium, wherein producing the medium comprises pressing the plurality of fruits to produce the fruit must. In some embodiments, the method further comprises removing solid fruit material from the fruit must to produce juice.
[0032] In some embodiments, the method comprises at least one additional fermentation process. In some embodiments, the method comprises carbonating a composition comprising ethanol.
[0033] In some aspects, the present disclosure provides a composition comprising ethanol produced, obtained, or obtainable by one of the methods described herein. In some embodiments, the composition comprising ethanol comprises at least 200 μg / L of ethyl hexanoate. In some embodiments, the composition comprising ethanol comprises less than 10 mg / L of hexanoic acid. [Brief explanation of the drawings]
[0034] Brief description of the drawings Further aspects of the present disclosure will be readily appreciated upon review of the following detailed description of its various aspects and embodiments when considered in conjunction with the accompanying drawings. [Figure 1]Figures 1A and 1B show the production of ethyl hexanoate and hexanoic acid by the engineered brewing yeast strains in malt extract fermentation. Figure 1A shows the fold change in ethyl hexanoate and hexanoic acid production by the engineered brewing yeast strains compared to the parent wild-type Saccharomyces cerevisiae CA01 strain. Figure 1B shows the concentrations of ethyl hexanoate (mg / L) and hexanoic acid (mg / L) produced by Saccharomyces cerevisiae strain y1210 or the wild-type Saccharomyces cerevisiae CA01 strain. Each bar reports the mean of two biological replicates. Error bars indicate standard deviation. Strains were wild-type Saccharomyces cerevisiae CA01 (CA01); CA01 expressing FAS2_G1250S and MpAAT1_A169G / A170F (y1059); CA01 expressing FAS2_G1250S and MpAAT1_A169G / A170F and containing deletion EHT1 (y1227); CA01 expressing FAS2_G1250S and MpAAT1_A169G / A170F and containing deletion EHT1 and EEB1 (y1076); These correspond to CA01, which expresses T1_A169G / A170F and contains deletions of EHT1, EEB1, and MGL2 (y1170); CA01, which expresses FAS2_G1250S, MpAAT1_A169G / A170F, and HCS and contains deletions of EHT1, EEB1, and MGL2 (y1210); and CA01, which expresses FAS2 and MpAAT1_A169G / A170F and contains deletions of EHT1 and EEB1 (y1232).
[0035] [Figure 2]Figures 2A and 2B show the production of ethyl hexanoate and hexanoic acid by the engineered wine yeast strains in grape juice fermentation. Figure 2A shows the concentrations of ethyl hexanoate (mg / L) and hexanoic acid (mg / L) produced by the engineered wine yeast strains and the wild-type parent Saccharomyces cerevisiae EC1118 strain. Figure 2B shows the ratio of ethyl hexanoate to hexanoic acid produced by each of the indicated strains. The values for the ethyl hexanoate and hexanoic acid concentrations are from Figure 2A. Each bar reports the average of two biological replicates. Error bars indicate the standard deviation. The strains were wild-type S. cerevisiae EC1118 (EC1118), S. cerevisiae Elegance expressing FAS2_G1250S and MaWES1-A144F / A360I (SEQ ID NO: 4; y786); S. cerevisiae Elegance expressing FAS2_G1250S and MaWES1 and containing deletions of EHT1 and EEB1 (y1080); S. cerevisiae EC1118 expressing FAS2_G1250S and MaWES1 (y796); S. cerevisiae EC1118 expressing FAS2_G1250S and MaWES1 and containing deletions of EHT1 and EEB1 (y1115). EC1118; corresponding to S. cerevisiae EC1118 expressing FAS2_G1250S and MpAAT1_A169G / A170F(y1134); and S. cerevisiae EC1118 expressing FAS2_G1250S and MpAAT1_A169G / A170F and containing deletions of EHT1 and EEB1(y1138). DETAILED DESCRIPTION OF THE INVENTION
[0036] Detailed Description Fruity tropical fruit flavors are highly desired by consumers in the fermented beverage market. Pineapple, guava, and berry flavors are particularly popular, as evidenced by the strong sales of Chardonnay and Sauvignon Blanc wines and beers produced with tropical-flavored hops. The presence of these flavors in both fruits and fermented beverages is due to various flavor-acting molecules that collectively impart a unique taste and aroma when consumed. One such molecule, ethyl hexanoate, contributes to many fruity tropical fruit flavors. When isolated, ethyl hexanoate is perceived as pineapple, but also contributes to the flavors of mango, apple, guava, and many other fruits. The genetically modified yeast cells and methods described herein are intended to increase the concentration of ethyl hexanoate produced during fermentation, such as for the production of beer or wine.
[0037] Several groups have attempted to modify yeast strains to increase ethyl hexanoate production during the fermentation process. However, these efforts have not led to the development of commercially viable yeast strains with enhanced ethyl hexanoate production due to challenges in reconciling the strain phenotypes of increased ethyl hexanoate production, unchanged growth rate, and minimal production of the off-flavor molecule hexanoic acid. In contrast, the genetically modified cells described herein are capable of producing increased levels of ethyl hexanoate, reduced levels of off-flavors (e.g., hexanoic acid), and have substantially unchanged growth characteristics.
[0038] Ethyl hexanoate concentrations vary widely among different beer and wine varieties, ranging from less than 100 μg / L to more than 1500 μg / L (see, for example, Avram et al. Anal. Lett. (2015). 48:1099-1116; Niu et al. J. Chromatogr. B. (2011). 879:2287-2293; Holt et al. FEMS Microbiol Rev. (2019). 43:193-222). This variation in ethyl hexanoate concentrations is due in part to differences in specific grape, barley, or hop varietals. These varietals are used as starting materials for their fermentation, but are also influenced by the yeast strain used in the fermentation process. While some yeast strains can produce fermented beverages with fruity flavors, the concentrations of ethyl hexanoate produced often barely exceed the human detection threshold. As a result, the fruity flavor associated with ethyl hexanoate is often subtle or barely noticeable, especially after the addition of other ingredients, such as strong flavoring hops, to the beverage.
[0039] Provided herein are genetically modified yeast cells engineered to express an enzyme having alcohol-O-acyltransferase (AAT) activity and an enzyme having fatty acid synthase (FAS2) activity. In some embodiments, the enzyme having AAT activity is modified to increase the production of ethyl hexanoate and / or reduce the production of undesirable hexanoic acid. Also provided herein are methods for producing fermented beverages, involving contacting genetically modified yeast cells with a medium containing a sugar source, including at least one fermentable sugar, during a fermentation process. Also provided herein are methods for producing ethanol (including compositions containing ethanol), involving contacting genetically modified yeast cells with a medium containing a sugar source, including at least one fermentable sugar, during a fermentation process.
[0040] Alcohol-O-acyltransferase (AAT) enzyme The genetically modified cells described herein contain a gene encoding an enzyme with alcohol-O-acyltransferase (AAT) activity. In some embodiments, the gene is a heterologous gene. The term "heterologous gene," as used herein, refers to a nucleic acid (e.g., DNA) sequence containing genetic instructions that are introduced into and expressed by a host organism (e.g., a genetically modified cell) that does not naturally encode a transgene. A heterologous gene may encode an enzyme that is not typically expressed by the cell, or a variant of an enzyme (e.g., a mutated enzyme) that is not typically expressed by the cell.
[0041] Alcohol-O-acyltransferase, sometimes referred to as acetyl-CoA:acetyltransferase or alcohol acetyltransferase, is a bisubstrate enzyme that catalyzes the transfer of an acyl chain from an acyl-coenzyme A (CoA) donor to an acceptor alcohol, resulting in the production of an acyl ester. The acyl esters present in fermented beverages influence their flavor. Ethyl hexanoate, an ester formed by the condensation of ethanol with either hexanoic acid or hexanoyl-CoA, imparts a pineapple flavor to fermented beverages such as beer and wine.
[0042] In some embodiments, the heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity is a wild-type alcohol-O-acyltransferase gene (e.g., a gene isolated from an organism). In some embodiments, the heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity is a mutant alcohol-O-acyltransferase gene that contains one or more mutations (e.g., substitutions, deletions, insertions) in the nucleic acid sequence of the alcohol-O-acyltransferase gene and / or in the amino acid sequence of the enzyme with alcohol-O-acyltransferase activity. As will be understood by those skilled in the art, mutations in the nucleic acid sequence may change the amino acid sequence of the translated polypeptide (e.g., substitution mutations) or may not change the amino acid sequence of the translated polypeptide (e.g., silent mutations) compared to the wild-type or reference enzyme.
[0043] In some embodiments, the heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity is truncated, i.e., lacking one or more amino acids, preferably at the N-terminus or C-terminus of the enzyme, compared to the wild-type or reference enzyme.
[0044] In some embodiments, the alcohol-O-acyltransferase is obtained from a bacterium or a fungus, including a yeast, hi some embodiments, the alcohol-O-acyltransferase is obtained from Marinobacter hydrocarbonoclasticus, Saccharomyces cerevisiae, Neurospora sitophila, Fragaria x ananassa, Actinidia deliciosa, Actinidia chinensis, Marinobacter aquaeolei, Saccharomycopsis fibuligera, Malus x domestica, or Solanum pennellii.
[0045] An exemplary alcohol-O-acyltransferase is MaWES from Marinobacter aquaeolei, defined by accession number WP_011783747.1, the amino acid sequence of which is represented as SEQ ID NO:1.
[0046] Amino acid sequence of wild-type MaWES from Marinobacter aquaeolei MTPLNPTDQLFLWLEKRQQPMHVGGLQLFSFPEGAPDDYVAQLADQLRQKTEVTAPFNQRLSYRLGQPVWVEDEHLDLEHHFRFEALPTPGRIRELLSFVSAEHSHLMDRERPMW EVHLIEGLKDRQFALYTKVHHSLVDGVSAMRMATRMLSENPDEHGMPPIWDLPCLSRDRGESDGHSLWRSVTHLLGLSGRQLGTIPTVAKELLKTINQARKDPAYDSIFHAPRCML NQKITGSRRFAAQSWCLKRIRAVCEAYGTTVNDVVTAMCAAALRTYLMNQDALPEKPLVAFVPVSLRRDDSSGGNQVGVILASLHTDVQEAGERLLKIHHGMEEAKQRYRHMSPEEIVNYTALTLAPAAFHLLTGLAPKWQTFNVVISNVPGPSRPLYWNGAKLEGMYPVSIDMDRLALNMTLTSYNDQVEFGLIGCRRTLPSLQRMLDYLEQGLAELELNAGL (SEQ ID NO: 1)
[0047] In some embodiments, the alcohol-O-acyltransferase is a homolog of MaWES from Marinobacter aquaeolei (SEQ ID NO: 1). Homologs or related enzymes may be identified using methods known in the art, such as those described herein.
[0048] In some embodiments, the alcohol-O-acyltransferase is obtained from a plant, such as a crop. In some embodiments, the alcohol-O-acyltransferase is from a strawberry plant. In some embodiments, the alcohol-O-acyltransferase gene is from a Fragraia species. In some embodiments, the alcohol-O-acyltransferase gene is from Fragraia x ananassa. The amino acid sequence of the wild-type MaWES homolog from Fx ananassa is given by accession number AAG13130.1 and has 17% sequence identity with MaWES from Marinobacter aquaeoleis (SEQ ID NO: 1). The catalytic histidine within the highly conserved HXXXD[A / G] motif is indicated in bold in SEQ ID NO: 2 below. This motif is highly conserved across AAT enzymes in plant and bacterial species. Plant homologs also have the highly conserved [N / D]FGWG (SEQ ID NO: 23) motif, underlined below.
[0049] Amino acid sequence of wild-type alcohol-O-acyltransferase from Fragraia x ananassa [ka] (SEQ ID NO: 2)
[0050] An exemplary alcohol-O-acyltransferase is SAAT from Fragaria x ananassa, as described, for example, in Beekwilder J, et al. Plant Physiol. (2004) 135(4):1865-78. In some embodiments, the amino acid sequence SAAT from Fragaria x ananassa is represented as SEQ ID NO: 14.
[0051] MGEKIEVSINSKHTIKPSTSSTPLQPYKLTLLDQLTPPAYVPIVFFYPITDHDFNLPQTLADLRQALSETLTLYYPLSGRVKNNLYIDDFEEGVPYLEARVNCDMTDFLRLRKIE CLNEFVPIKPFSMEAISDERYPLLGVQVNVFDSGIAIGVSVSHKLIDGGTADCFLKSWGAVFRGCRENIIHPSLSEAALLFPPRDDLPEKYVDQMEALWFAGKKVATRRFVFGVK AISSIQDEAKSESVPKPSRVHAVTGFLWKHLIAASRALTSGTTSTRLSIAAQAVNLRTRMNMETVLDNATGNLFWWAQAILELSHTTPEISDLKLCDLVNLLNGSVKQCNGDYFETFKGKEGYGRMCEYLDFQRTMSSMEPAPDIYLFSSWTNFFNPLDFGWGRTSWIGVAGKIESASCKFIILVPTQCGSGIEAWVNLEEEKMAMLEQDPHFLALASPKTLI (SEQ ID NO: 14)
[0052] In some embodiments, the alcohol-O-acyltransferase is from a tomato plant. In some embodiments, the alcohol-O-acyltransferase gene is from a Solanum species. In some embodiments, the alcohol-O-acyltransferase gene is from Solanum lycopersicum. In some embodiments, the alcohol-O-acyltransferase is from Solanum pennellii. An exemplary alcohol-O-acyltransferase is SpAAT1 from Solanum pennellii, as described, for example, in Goulet C, et al. Molecular Plant (2015) 8:1, 153-162. The amino acid sequence of the wild-type MaWES homolog from Solanum pennellii is given by accession number NP_001310384.1 and has 15% sequence identity with MaWES from Marinobacter aquaeolei (SEQ ID NO: 1). In some embodiments, the amino acid sequence of SpAAT1 from Solanum pennellii is represented as SEQ ID NO:3.
[0053] MANTLPISINYHKPKLVVPSSVTPHETKRLSEIDDQGFIRFQIPILMFYKYNSSMKGKDPARIIEDGLSKTLVFYHPLAGRLIEGPNKKLMVNCNGEGVLFIEGDANIELEK LGESIKPPCPYLDLLLHNVPGSDGIIGSPLLLIQVTRFTCGGFAVGFRVSHTMMDGYGFKMFLNALSELIQGASTPSILPVWQRHLLSARSSPCITCSHHEFDEEIESKIAW ESMEDKLIQESFFFGNEEMEVIKNQIPPNYGCTKFELLMAFLWKCRTIALDLHPEEIVRLTYVINIRGKKSLNIELPIGYYGNAFVTPVVVSKAGLLCSNPVTYAVELIKKVKDHINEEYIKSVIDLTVIKGRPELTKSWNFLVSDNRYIGFDEFDFGWGNPIFGGISKATSFISFGVSVKNDKGEKGVLIAISLPPLAMKKLQDIYNMTFRVIIPRI (SEQ ID NO: 3)
[0054] In some embodiments, the alcohol-O-acyltransferase is from Saccharomyces cerevisiae. An exemplary alcohol-O-acyltransferase is ScATF1 from Saccharomyces cerevisiae, as described, for example, in Verstrepen KJ, et al. Appl Microbiol Biotechnol. (2003) 61(3):197-205. The amino acid sequence of ScATF1 from Saccharomyces cerevisiae is represented as SEQ ID NO: 12. (SEQ ID NO: 12)
[0055] In some embodiments, the alcohol-O-acyltransferase is from Neurospora sitophila. An exemplary alcohol-O-acyltransferase is NsATF1 from Neurospora sitophila, the amino acid sequence of which is represented as SEQ ID NO:13. MGTSIPQPIRPLGPCEAYSSSRHALGFYRCLANTCRYAVPWSVLQGKSVPDVLEAAIANLVLRLPRLSVAITGDEASRPYFASVSSLDLSYHLECVELRAELDFHARDSHLLHMLEAQHNQLWPDVG FRPPWKVLAVYDPRPSQLEDRLILDIVLAIHHSLADGRSTAIFQTSLLDELNKPPVRPSCLEDHVLRMPSKPHGHILPPQEELVKFTTSWRFLAGTLWNEFVSGWLYKPATDLPWAGAPIRPDPYQT RLRLVTIPAKAVSQLLTNCRANETTLTPLLHVLILTSLARRLTAEAATSFQSCTPVDLRPFIQSGSHVADPAEVFGVLVTSASHSFNSSRVSGLREQASGEKIWSLAQTLRQELKDRLEAIPQDDMVSMLRWIANWRGFWLNKVNKPREHTLEVSNIGSLHGSPEKTANADLETGSKWQIVRSVMSQCAIVAGPALCASVSGVVGGPISIALSWQEGIIESELVEGVAHDLQLWMNQGGPVHGQRLP (SEQ ID NO: 13)
[0056] In some embodiments, the alcohol-O-acyltransferase is from Actinidia deliciosa. An exemplary alcohol-O-acyltransferase is AdAAT1 from Actinidia deliciosa, as described, for example, in Gunther CS, et al. Phytochemistry (2011) 72(8):700-10. In some embodiments, the amino acid sequence of AdAAT1 from Actinidia deliciosa is represented as SEQ ID NO: 15. MASSVRLVKKPVLVAPVDPTPSTVLSLSSLDSQLFLRFPIEYLLVYASPHGVDRAVTAARVKAALARSLVPYYPLAGRVKTRPDSTGLDVVCQAQGAGLLEAVSDYTASD FQRAPRSVTEWRKLLLVEVFKVVPPLVVQLTWLSDGVCVALGVGFSHCVIDGIGSSEFLNLFAELATGRARLSEFQPKPVWDRHLLNSAGRTNLGTHPEFGRVPDLSGFVT RFTQERLSPTSITFDKTWLKELKNIAMSTSQPGEFPYTSFEVLSGHIWRSWARSLNLPAKQVLKLLFSINIRNRVKPSLPAGYYGNAFVLGCAQTSVKDLTEKGLGYCADLVRGAKERVGDEYAREVVESVSWPRRASPDSVGVLIISQWSRLGLDRVDFGLGRPVQVGPICCDRYCLFLPVRDRTESVKVMVAVPTSAVDRYEYFIRSPYS (SEQ ID NO: 15)
[0057] In some embodiments, the alcohol-O-acyltransferase is from Actinidia chinensis. An exemplary alcohol-O-acyltransferase is AcAAT16 from Actinidia chinensis, as described, for example, in Gunther CS, et al. Phytochemistry (2011) 72(8):700-10. In some embodiments, the amino acid sequence of AcAAT16 from Actinidia chinensis is represented as SEQ ID NO: 16. MASFPPSLVFTVRRNEPTLVLPSKSTPRELKQLSDIDDQEGLRFQVPVIMFYKRKLSMEGEDPVKVIREALAEALVFYYPFAGRLIEGPNRKLMVDCTGEGVLFIEADADIEVNQL IGDTIDPGFSYLDELLHDVPGSEGILGCPLLLIQVTRFRCGGAFAIRLNHTMSDAPGLVQLLTTIAEFARGAEGAPSVPPVWQREFLAARQPPSITFQHHEYEQVINTTTDDNKS MTHKSFFFGPKEIRAIRSHFPPHYRSVSSTFDVLTACLWRCRTCALGLDPPKTVRISCAANGRGKHDLHVPRGYYGNVFAFPAVVSRAGMISTSSLEYTVEEVKKAKARMTGEYLRSVADLMVTKGRPLYTVAGNYIVSDTTRVGFDAIDFGWGKPVYGGPARAFPLISFYARFKNNRGEDGTVVLICLPEAAMKRFQDELKKMTEEHVDGPFEYKLIKVMSKL (SEQ ID NO: 16)
[0058] In some embodiments, the alcohol-O-acyltransferase is from Saccharomycopsis fibuligera. An exemplary alcohol-O-acyltransferase is SfATFA2 from Saccharomycopsis fibuligera, as described, for example, in Moon HY, et al. Systems and Synthetic Microbiology and Bioinformatics (2021) 59, 598-608. In some embodiments, the amino acid sequence of SfATFA2 from Saccharomycopsis fibuligera is represented as SEQ ID NO: 17. (SEQ ID NO: 17)
[0059] An exemplary alcohol-O-acyltransferase is SfATFB4 from Saccharomycopsis fibuligera, as described, for example, in Moon HY, et al. Systems and Synthetic Microbiology and Bioinformatics (2021) 59, 598-608. In some embodiments, the amino acid sequence of SfATFB4 from Saccharomycopsis fibuligera is represented as SEQ ID NO: 18. (SEQ ID NO: 18)
[0060] In some embodiments, the alcohol-O-acyltransferase is from Malus x domestica. An exemplary alcohol-O-acyltransferase is MpAAT1 from Malus x domestica, as described, for example, in Dunemann F, et al. Molecular Breeding (2012) 29, 609-625.
[0061] In some embodiments, the amino acid sequence of MpAAT1 from Malus x domestica is represented as SEQ ID NO:19. MMSFSVLQVKRLQPELITPAKSTPQETKFLSDIDDQESLRVQIPIIMCYKDNPSLNKNRNPVKAIREALSRALVYYYPLAGRLREGPNRKLVVDCNGEGILFVEASADVTLEQLG DKILPPCPLLEEFLYNFPGSDGIIDCPLLLIQVTCLTCGGFILALRLNHTMCDAAGLLLFLTAIAEMARGAHAPSILPVWERELLFARDPPRITCAHEYEDVIGHSDGSYASSNQ SNMVQRSFYFGAKEMRVLRKQIPPHLISTCSTFDLITACLWKCRTLALNINPKEAVRVSCIVNARGKHNNVRLPLGYYGNAFAFPAAISKAEPLCKNPLGYALELVKKAKATMNEEYLRSVADLLVLRGRPQYSSTGSYLIVSDNTRVGFGDVNFGWGQPVFAGPVKALDLISFYVQHKNNTEDGILVPMCLPSSAMERFQQELERITQEPKEDICNNLRSTSQ (SEQ ID NO: 19)
[0062] In some embodiments, the alcohol-O-acyltransferase is from Marinobacter hydrocarbonoclasticus. An exemplary alcohol-O-acyltransferase is MhWES2 from Marinobacter hydrocarbonoclasticus, as described by Holtzeapple E, et al. Journal of Bacteriology (2007) 189:10. In some embodiments, the alcohol-O-acyltransferase is MhWES2 from Marinobacter hydrocarbonoclasticus and comprises one or more mutations (e.g., substitutions, insertions, deletions). In some embodiments, the alcohol-O-acyltransferase is MhWES2 from Marinobacter hydrocarbonoclasticus and does not comprise a glycine (G) residue at position 150. In some embodiments, the alcohol-O-acyltransferase is MhWES2 from Marinobacter hydrocarbonoclasticus and comprises a phenylalanine (F) residue at position 150. The amino acid sequence of MhWES2 from Marinobacter hydrocarbonoclasticus, containing a phenylalanine at the position corresponding to 150, is represented as SEQ ID NO:21. MGKRLGTLDASWLAVESEDTPMHVGTLQIFSLPEGAPETFLRDMVTRMKEAGDVAPPWGYKLAWSGFLGRVIAAPAWKVDKDIDLDYHVRHSALPRPGGERELGILVSRLHSNPLDFSRPL WECHVIEGLENNNRFALYTKMHHSMIDGISFVRLMQRVLTTDPERCNMPPPWTVRPHQRRGAKTDKEASVPAAVSQAMDALKLQADMAPRLWQAGNRLVHSVRHPEDGLTAPFTGPVSVLNH RVTAQRRFATQHYQLDRLKNLAHASGGSLNDIVLYLCGTALRRFLAEQNNLPDTPLTAGIPVNIRPADDEGTGTQISFMIASLATDEADPLNRLQQIKTSTRRAKEHLQKLPKSALTQYTMLLMSPYILQLMSGLGGRMRPVFNVTISNVPGPEGTLYYEGARLEAMYPVSLIAHGGALNITCLSYAGSLNFGFTGCRDTLPSMQKLAVYTGEALDELESLILPPKKRARTRK (SEQ ID NO: 21)
[0063] Amino acids of alcohol-O-acyltransferases may be modified (e.g., substituted) to produce variants of alcohol-O-acyltransferases. For example, as described herein, the amino acids at positions 144 and / or 360, designated alanine 144 and alanine 360, respectively, of SEQ ID NO: 1 may be mutated to produce alcohol-O-acyltransferase enzymes with desired activities, such as increased production of ethyl hexanoate during fermentation, increased production of hexanoic acid during fermentation, and / or an increased ratio of ethyl hexanoate to hexanoic acid production. In some embodiments, the amino acids corresponding to alanine 144 and / or alanine 360 of SEQ ID NO: 1 may be substituted with an amino acid that is not an alanine residue (e.g., any other amino acid).
[0064] In some embodiments, the amino acid corresponding to alanine (A144) at position 144 of SEQ ID NO: 1 is substituted with an amino acid selected from histidine (H), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (G), cysteine (C), glycine (G), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some embodiments, the amino acid corresponding to alanine (A144) at position 144 of SEQ ID NO: 1 is substituted with a hydrophobic amino acid (e.g., histidine (H), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), tryptophan (W)). In some embodiments, the amino acid corresponding to alanine at position 144 of SEQ ID NO:1 (A144) is substituted with a phenylalanine (F) residue (A144F).
[0065] In some embodiments, the amino acid corresponding to alanine (A360) at position 360 of SEQ ID NO: 1 is substituted with an amino acid selected from histidine (H), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (G), cysteine (C), glycine (G), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some embodiments, the amino acid corresponding to alanine (A360) at position 360 of SEQ ID NO: 1 is substituted with a hydrophobic amino acid (e.g., histidine (H), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), tryptophan (W)). In some embodiments, the amino acid corresponding to alanine at position 360 of SEQ ID NO:1 (A360) is substituted with an isoleucine (I) residue (A360I).
[0066] In some embodiments, the amino acid corresponding to alanine at position 144 of SEQ ID NO:1 (A144) is substituted with a phenylalanine (F) residue (A144F), and the amino acid corresponding to alanine at position 360 of SEQ ID NO:1 (A360) is substituted with an isoleucine (I) residue (A360I), as defined by SEQ ID NO:4.
[0067] Amino acid sequence of variant MaWES from Marinobacter hydrocarbonoclasticus - A144F and A360I mutations (A144F and A360I) [ka] (SEQ ID NO: 4)
[0068] In some embodiments, the alcohol-O-acyltransferase is from Malus x domestica or a variant thereof. An exemplary alcohol-O-acyltransferase is MpAAT1 from Malus x domestica, as described, for example, in Dunemann F. et al. Molecular Breeding (2012) 29, 609-625. In some embodiments, the alcohol-O-acyltransferase is MpAAT1 from Malus x domestica and includes one or more mutations (e.g., substitutions, insertions, deletions).
[0069] In some embodiments, the amino acid corresponding to alanine (A169) at position 169 of SEQ ID NO: 19 is substituted with an amino acid selected from histidine (H), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (Q), cysteine (C), glycine (G), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some embodiments, the amino acid corresponding to alanine (A169) at position 169 of SEQ ID NO: 19 is substituted with a glycine (G) residue (A169G).
[0070] In some embodiments, the amino acid corresponding to alanine (A170) at position 170 of SEQ ID NO: 19 is substituted with an amino acid selected from histidine (H), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (Q), cysteine (C), glycine (G), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some embodiments, the amino acid corresponding to alanine (A170) at position 170 of SEQ ID NO: 19 is substituted with a phenylalanine (F) residue (A170F).
[0071] In some embodiments, the alcohol-O-acyltransferase is MpAAT1 from Malus x domestica, which, relative to SEQ ID NO: 19, comprises a glycine (G) at residue 169 and a phenylalanine at residue 170. The amino acid sequence of MpAAT1 from Malus x domestica, which comprises a glycine at residue 169 and a phenylalanine at residue 170, is represented as SEQ ID NO: 20. MMSFSVLQVKRLQPELITPAKSTPQETKFLSDIDDQESLRVQIPIIMCYKDNPSLNKNRNPVKAIREALSRALVYYYPLAGRLREGPNRKLVVDCNGEGILFVEASADVTLEQLG DKILPPCPLLEEFLYNFPGSDGIIDCPLLLIQVTCLTCGGFILALRLNHTMCDGFGLLLFLTAIAEMARGAHAPSILPVWERELLFARDPPRITCAHEYEDVIGHSDGSYASSNQ SNMVQRSFYFGAKEMRVLRKQIPPHLISTCSTFDLITACLWKCRTLALNINPKEAVRVSCIVNARGKHNNVRLPLGYYGNAFAFPAAISKAEPLCKNPLGYALELVKKAKATMNEEYLRSVADLLVLRGRPQYSSTGSYLIVSDNTRVGFGDVNFGWGQPVFAGPVKALDLISFYVQHKNNTEDGILVPMCLPSSAMERFQQELERITQEPKEDICNNLRSTSQ (SEQ ID NO: 20)
[0072] In some embodiments, the enzyme comprises the amino acid sequence of any one of SEQ ID NOS: 1-4 and 12-22. In some embodiments, the enzyme comprises the amino acid sequence of any one of SEQ ID NOS: 1-3, except that the amino acid corresponding to alanine at position 144 (A144) and / or the amino acid corresponding to alanine at position 360 (A360), based on the reference sequence set forth in SEQ ID NO: 1, is substituted with a hydrophobic amino acid (e.g., histidine (H), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), tryptophan (W)). In some embodiments, the amino acid corresponding to position 144 (A144) is substituted with phenylalanine (F), and / or the amino acid corresponding to position 360 (A360) is substituted with isoleucine (I).
[0073] In some embodiments, the heterologous gene encodes an enzyme with alcohol-O-acyltransferase activity, such that cells expressing the enzyme are able to produce increased levels of ethyl hexanoate compared to cells that do not express the heterologous gene. In some embodiments, the heterologous gene encodes an enzyme with alcohol-O-acyltransferase activity, such that cells expressing the enzyme are able to produce increased levels of ethyl hexanoate compared to cells expressing an enzyme with wild-type alcohol-O-acyltransferase activity. In some embodiments, the heterologous gene encodes an enzyme with alcohol-O-acyltransferase activity, such that cells expressing the enzyme are able to produce reduced levels of hexanoic acid compared to cells that do not express the heterologous gene. In some embodiments, the heterologous gene encodes an enzyme with alcohol-O-acyltransferase activity, such that cells expressing the enzyme are able to produce reduced levels of hexanoic acid compared to cells expressing an enzyme with wild-type alcohol-O-acyltransferase activity. In some embodiments, the enzyme with alcohol-O-acyltransferase activity capable of producing increased levels of ethyl hexanoate contains an amino acid substitution at a position corresponding to alanine at position 144 (A144) and / or alanine at position 360 (A360) of SEQ ID NO: 1. In some embodiments, the enzyme with alcohol-O-acyltransferase activity capable of producing increased levels of ethyl hexanoate has a sequence set forth in any one of SEQ ID NOs: 2-4 and 12-22.
[0074] In some embodiments, the enzyme with alcohol-O-acyltransferase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 1-4 and 12-22. In some embodiments, the enzyme with alcohol-O-acyltransferase activity has an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a sequence as set forth in any one of SEQ ID NOs:1-4 and 12-22, wherein the amino acid corresponding to alanine at position 144 of SEQ ID NO:1 (A144) and / or the amino acid corresponding to alanine at position 360 of SEQ ID NO:1 (A360) is substituted with an amino acid that is not an alanine residue (e.g., any other amino acid).In some embodiments, the enzyme with alcohol-O-acyltransferase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 1-4 and 12-22, and has an acyltransferase activity at position 144 of SEQ ID NO: 1. The amino acid corresponding to alanine (A144) and / or the amino acid corresponding to alanine (A360) at position 360 of SEQ ID NO: 1 is substituted with an amino acid selected from histidine (H), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (G), cysteine (C), glycine (G), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W).
[0075] The terms "percent identity," "sequence identity," "% identity," "% sequence identity," and "% identical," which may be used interchangeably herein, refer to a quantitative measurement of similarity between two sequences (e.g., nucleic acids or amino acids). Percent identity can be determined using the algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, modified as in Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm has been incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul et al., J. Mol. Biol. 215:403-10, 1990. BLAST protein searches can be performed with the XBLAST program, score=50, word length=3, to obtain amino acid sequences homologous to the protein molecule of interest. When gaps exist between the two sequences, Gapped BLAST can be used as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When using BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.
[0076] Where a percent identity or range thereof (e.g., at least, more, etc.) is specified, unless otherwise specified, endpoints are intended to be encompassed, and a range (e.g., at least 70% identity) includes all ranges within the recited range (e.g., at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least "identity" includes "at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identity) and all increments thereof (e.g., tenths of a percent (i.e., 0.1%), hundredths of a percent (i.e., 0.01%), etc.).
[0077] In some embodiments, the enzyme with alcohol-O-acyltransferase activity comprises an amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of an amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the enzyme with alcohol-O-acyltransferase activity comprises an amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of an amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the enzyme with alcohol-O-acyltransferase activity comprises an amino acid sequence as set forth in SEQ ID NO: 3. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of an amino acid sequence as set forth in SEQ ID NO: 3. In some embodiments, the enzyme with alcohol-O-acyltransferase activity comprises an amino acid sequence as set forth in SEQ ID NO: 4. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of an amino acid sequence as set forth in SEQ ID NO: 4.
[0078] In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 12. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 13. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 14. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 15. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 16. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 19. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO: 20. In some embodiments, the enzyme with alcohol-O-acyltransferase activity consists of the amino acid sequence as set forth in SEQ ID NO:21.
[0079] In some embodiments, the gene encoding an enzyme having alcohol-O-acyltransferase activity comprises a nucleic acid sequence encoding an enzyme comprising an amino acid sequence having at least 80% (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9%) sequence identity to any one of SEQ ID NOs: 1-4 and 12-22. In some embodiments, the gene encoding an enzyme having alcohol-O-acyltransferase activity comprises a nucleic acid sequence encoding an enzyme consisting of an amino acid sequence as represented by any one of SEQ ID NOs: 1 to 4 and 12 to 22.
[0080] Identification of additional enzymes that have alcohol-O-acyltransferase activity or are predicted to have alcohol-O-acyltransferase activity may be carried out based on similarity or homology to one or more domains of an alcohol-O-acyltransferase, such as, for example, an alcohol-O-acyltransferase set forth in any one of SEQ ID NOs: 1-4 and 12-22. In some embodiments, enzymes for use in the modified cells and methods described herein may be identified based on similarity or homology to an activity domain, such as a catalytic domain, such as a catalytic domain associated with alcohol-O-acyltransferase activity. In some embodiments, an enzyme for use in the modified cells and methods described herein may have a relatively high level of sequence identity to a reference alcohol-O-acyltransferase (e.g., a wild-type alcohol-O-acyltransferase such as any of SEQ ID NOs: 1, 2, 3, 12, 13, 14, 15, 16, 17, 18, 19, or 22), based on analysis over most of the enzyme or the full length of the enzyme, but has a relatively low level of sequence identity to the reference alcohol-O-acyltransferase in the region of the catalytic domain. In some embodiments, an enzyme for use in the modified cells and methods described herein has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity in the region of the catalytic domain of the enzyme compared to a reference alcohol-O-acyltransferase (e.g., SEQ ID NO:1).
[0081] In some embodiments, an enzyme for use in the modified cells and methods described herein has a relatively high level of sequence identity in the region of the catalytic domain of the enzyme compared to a reference alcohol-O-acyltransferase (e.g., any of SEQ ID NOS: 1-3) based on analysis of a majority of the enzyme or over the full length of the enzyme, and a relatively low level of sequence identity to the reference alcohol-O-acyltransferase. In some embodiments, an enzyme for use in the modified cells and methods described herein has at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least a little more than a majority of the enzyme or over the full length of the enzyme compared to a reference alcohol-O-acyltransferase (e.g., SEQ ID NOS: 1-4, 12-19, and 21-22). The sequence identity of the fragments may be at least 65%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9%.
[0082] In some embodiments, the amino acid substitution(s) may be in the active site. As used herein, the term "active site" refers to the region of an enzyme with which a substrate interacts. The amino acids comprising and surrounding the active site, including the functional groups of each amino acid, may contribute to the size, shape, and / or substrate accessibility of the active site. In some embodiments, the alcohol-O-acyltransferase variant contains one or more modifications that are substitutions of selected amino acids with amino acids having different functional groups.
[0083] This information can also be used to identify positions, e.g., corresponding positions, in other enzymes that have or are predicted to have alcohol-O-acyltransferase activity. As will be apparent to those skilled in the art, amino acid substitutions at positions identified in one alcohol-O-acyltransferase enzyme can also be made at corresponding amino acid positions in another alcohol-O-acyltransferase enzyme. In such cases, one of the alcohol-O-acyltransferase enzymes may be used as a reference enzyme. For example, as described herein, amino acid substitutions at positions A144 and / or A360 of MaWES from Marinobacter aquaeolei (SEQ ID NO: 1) have been shown to increase production of ethyl hexanoate and / or decrease production of hexanoic acid. Similar amino acid substitutions can be made at corresponding positions in other enzymes with alcohol-O-acyltransferase activity, using MaWES as a reference (e.g., SEQ ID NO: 1). For example, amino acid substitutions can be made at the corresponding position(s) of an alcohol-O-acyltransferase from F. ananassa or S. lycopersicum as described herein, using MaWES as a reference (e.g., SEQ ID NO: 1). In some embodiments, the amino acid in another enzyme (e.g., alcohol-O-acyltransferase from F. ananassa (see, e.g., SEQ ID NO: 2)) at positions corresponding to positions A144 and / or A360 of MaWES from M. hydrocarbonoclasticus (SEQ ID NO: 1) is not alanine. In some embodiments, the amino acid in another enzyme (e.g., alcohol-O-acyltransferase from S. lycopersicum (see, e.g., SEQ ID NO: 3)) at positions corresponding to positions A144 and / or A360 of MaWES from M. hydrocarbonoclasticus (SEQ ID NO: 1) is not alanine.
[0084] The variants of the alcohol-O-acyltransferases described herein contain amino acid substitutions at one or more positions corresponding to the reference alcohol-O-acyltransferase. In some embodiments, the variants of the alcohol-O-acyltransferases contain amino acid substitutions at one, two, three, four, five, or more positions corresponding to the reference alcohol-O-acyltransferase. In some embodiments, the alcohol-O-acyltransferase is a non-naturally occurring (e.g., genetically modified) alcohol-O-acyltransferase. In some embodiments, the alcohol-O-acyltransferase does not have the amino acid sequence set forth in SEQ ID NO: 1.
[0085] The genetically modified cells described herein, in some embodiments, contain a genetic modification that reduces the expression and / or activity of an endogenous gene encoding an enzyme with alcohol-O-acyltransferase (AAT) activity. The term "endogenous gene," as used herein, refers to a hereditary unit that contains genetic instructions that occur within a host organism (e.g., a genetically modified cell) and corresponds to a nucleic acid (e.g., DNA) sequence that is expressed by the host organism.
[0086] The Saccharomyces cerevisiae yeast genome encodes at least seven alcohol-O-transferases believed to possess abundant ester and acyl-CoA hydrolysis activity. Non-limiting examples of endogenous S. cerevisiae genes encoding enzymes with alcohol-O-acyltransferase activity include Atf1p, Atf2p, Eat1p, Eht1p, Eeb1p, Iah1p, and Mgl2p, and the corresponding protein products ATF1, ATF2, EAT1, EHT1, EEB1, IAH1, and MGL2. In some embodiments, the modified cells do not express endogenous Eeb1p or endogenous EEB1. Methods for reducing the expression and / or activity of a desired gene are well known in the art. For example, the promoter controlling the expression of the endogenous gene may be modified to be less permissive for transcription initiation, resulting in reduced transcription in the modified cells, and thus less protein production and lower enzyme activity. Alternatively, the epigenome may be methylated or otherwise modified to inhibit transcription, which results in reduced protein production and consequently lower enzyme activity in the modified cells.
[0087] In some embodiments, endogenous genes encoding one or more alcohol-O-acyltransferases are deleted from the genome of the modified cell. Methods for deleting genes from the genome of an organism are well known in the art. For example, a DNA construct encoding a non-functional gene, or alternatively a reporter or drug resistance gene, flanking DNA sequences corresponding to the 5' and 3' regions flanking the endogenous gene in the genome may be introduced into the target cell where it may be integrated into the target region for homologous recombination. In some embodiments, one or more endogenous genes encoding one or more alcohol-O-acyltransferases are deleted from the genome of the modified cell. In some embodiments, the Eeb1p gene or a portion thereof is replaced by homologous recombination. In some embodiments, after recombination, the genome of the cell does not contain an intact Eeb1p gene, and therefore the cell is deficient in EEB1 activity. In some embodiments, the Eht1 gene or a portion thereof is replaced by homologous recombination. In some embodiments, after recombination, the genome of the cell does not contain an intact Eht1 gene, and thus the cell is deficient in EHT1 activity. In some embodiments, the Mgl2 gene, or a portion thereof, has been replaced by homologous recombination. In some embodiments, after recombination, the genome of the cell does not contain an intact Mgl2 gene, and thus the cell is deficient in MGL2 activity. In some embodiments, the Eht1 gene and the Eeb1p gene, or portions thereof, have been replaced by homologous recombination. In some embodiments, after recombination, the genome of the cell does not contain an intact Eht1 gene or Eeb1p gene, and thus the cell is deficient in EHT1 activity and EEB1 activity. In some embodiments, the Eht1 gene and the Mgl2 gene, or portions thereof, have been replaced by homologous recombination. In some embodiments, after recombination, the genome of the cell does not contain an intact Eht1 gene or Mgl2 gene, and thus the cell is deficient in EHT1 activity and MGL2 activity. In some embodiments, the Eeb1p and Mgl2 genes, or portions thereof, are replaced by homologous recombination.In some embodiments, the recombination has occurred and the genome of the cell does not contain an intact Eeb1p or Mgl2 gene, and thus the cell is deficient in EEB1 and MGL2 activity. In some embodiments, the Eeb1p, Eht1, and Mgl2 genes, or portions thereof, have been replaced by homologous recombination. In some embodiments, the recombination has occurred and the genome of the cell does not contain an intact Eeb1p, Eht1, or Mgl2 gene, and thus the cell is deficient in EEB1, EHT1, and MGL2 activity.
[0088] In some embodiments, the endogenous gene encoding one or more alcohol-O-acyltransferases is modified to reduce alcohol-O-acyltransferase activity. For example, one or more mutations may be made in the endogenous gene encoding the alcohol-O-acyltransferase (e.g., one or more mutations in any of Eeb1p, Eht1, and / or Mgl2) such that the enzyme has reduced or eliminated alcohol-O-acyltransferase activity.
[0089] Fatty acid synthase 2 (FAS2) enzyme The genetically modified cells described herein contain a gene encoding an enzyme with fatty acid synthase (FAS2) activity. In some embodiments, the gene is an exogenous gene. The term "exogenous gene," as used herein, refers to a genetic unit corresponding to a sequence of nucleic acid (e.g., DNA) containing genetic instructions that is introduced into a host organism (e.g., a genetically modified cell) from an external source and expressed by the host organism. In some embodiments, the exogenous gene is an additional copy of a gene present in the cell.
[0090] Metabolites produced during fermentation can impart distinctive flavors to fermented beverages. As discussed herein, ethyl hexanoate, for example, is a fatty acid ester that imparts a pineapple flavor. However, hydrolysis of the ester bond of ethyl hexanoate results in the formation of ethanol and hexanoic acid (a pungent fatty acid that, when present at concentrations above the flavor detection threshold, imparts a cheese-like, rancid, goat-like flavor). Consequently, producing hexanoic acid during the production of fermentation products intended for consumption is undesirable, as beverages containing hexanoic acid at concentrations above the flavor detection threshold are widely considered undrinkable and commercially unviable. Thus, to produce fermented beverages that are considered palatable and commercially viable, compositions and methods for increasing the production of ethyl hexanoate during fermentation must do so while minimizing the production of hexanoic acid to levels below the flavor detection threshold.
[0091] The fatty acid synthetase complex contains six polypeptide α subunits (encoded by FAS2) and six polypeptide β subunits (encoded by FAS1). The α subunit, referred to herein as "FAS2," is believed to be involved in fatty acid chain elongation and to affect the production of hexanoyl-CoA, which may be used to form both ethyl hexanoate and hexanoic acid during fermentation.
[0092] The genetically modified cells described herein may express a gene, such as an exogenous gene encoding an enzyme having fatty acid synthase (FAS2) activity. In some embodiments, the enzyme having fatty acid synthase (FAS2) activity is obtained from a bacterium or a fungus. In some embodiments, the enzyme having fatty acid synthase (FAS2) activity is obtained from a yeast. In some embodiments, the enzyme having fatty acid synthase (FAS2) activity is from a Saccharomyces species. In some embodiments, the enzyme having fatty acid synthase (FAS2) activity is from a Saccharomyces cerevisiae.
[0093] An exemplary enzyme having fatty acid synthase activity is FAS2 from Saccharomyces cerevisiae WLP001, which is defined by the amino acid sequence set forth as SEQ ID NO:5.
[0094] An additional exemplary enzyme having fatty acid synthase activity is FAS2 from Saccharomyces cerevisiae 288c, which is defined by accession number P19097-1 and represented as SEQ ID NO:11.
[0095] In some embodiments, the fatty acid synthase is a homolog of FAS2 from S. cerevisiae (SEQ ID NO: 5). In some embodiments, an enzyme having fatty acid synthase activity may be modified (e.g., mutated) to adjust the activity of the enzyme.
[0096] Amino acids of fatty acid synthases may be modified (e.g., substituted) to produce FAS2 variants. For example, as described herein, the amino acid glycine at position 1250, designated glycine 1250 (G1250) of SEQ ID NO: 5, may be mutated to produce a FAS2 enzyme with a desired activity, such as increased production of ethyl hexanoate and / or decreased production of hexanoic acid during fermentation. In some embodiments, the amino acid corresponding to glycine 1250 of SEQ ID NO: 5 is substituted with an amino acid that is not a glycine residue (e.g., any other amino acid).
[0097] In some embodiments, the amino acid corresponding to glycine (G1250) at position 1250 of SEQ ID NO: 5 is substituted with an amino acid selected from alanine (A), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (G), cysteine (C), histidine (H), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W).
[0098] In some embodiments, the amino acid corresponding to glycine (G1250) at position 1250 of SEQ ID NO:5 is substituted with a nonpolar amino acid (e.g., alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M), tryptophan (W), phenylalanine (F), proline (P)). In some embodiments, the amino acid corresponding to glycine (G1250) at position 1250 of SEQ ID NO:5 is substituted with a polar amino acid (e.g., serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (G)). In some embodiments, the amino acid corresponding to glycine (G1250) at position 1250 of SEQ ID NO:5 is substituted with a serine (S) residue (G1250S), as set forth in SEQ ID NO:6. The substituted amino acid is shown below in bold and underlined.
[0099] Amino acid sequence of variant FAS2 from Saccharomyces cerevisiae – G1250S mutation [ka] (SEQ ID NO: 6)
[0100] In some embodiments, the enzyme with fatty acid synthase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence as set forth in SEQ ID NO:5 or 6. In some embodiments, the enzyme with fatty acid synthase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence as set forth in SEQ ID NO: 5 or 6, and contains a substitution mutation at the amino acid corresponding to glycine at position 1250 (G1250) of SEQ ID NO: 5. In some embodiments, the enzyme with fatty acid synthase activity contains a substitution mutation at the amino acid corresponding to glycine at position 1250 (G1250) of SEQ ID NO: 5 with an amino acid that is not a glycine residue (e.g., any other amino acid).In some embodiments, an enzyme with fatty acid synthase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence as set forth in SEQ ID NO:5, and The amino acid corresponding to glycine at position 50 (G1250) is substituted with an amino acid selected from histidine (H), arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (G), cysteine (C), alanine (A), proline (P), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some embodiments, the enzyme with fatty acid synthase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence as set forth in SEQ ID NO:6.
[0101] In some embodiments, the enzyme with fatty acid synthase activity comprises an amino acid sequence as set forth in SEQ ID NO: 5. In some embodiments, the enzyme with fatty acid synthase activity consists of an amino acid sequence as set forth in SEQ ID NO: 5. In some embodiments, the enzyme with fatty acid synthase activity comprises an amino acid sequence as set forth in SEQ ID NO: 6. In some embodiments, the enzyme with fatty acid synthase activity consists of an amino acid sequence as set forth in SEQ ID NO: 6.
[0102] In some embodiments, the gene encoding the enzyme having fatty acid synthase activity comprises a nucleic acid sequence encoding an enzyme comprising an amino acid sequence having at least 80% (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9%) sequence identity to the sequence as set forth in SEQ ID NO: 5 or 6. In some embodiments, the gene encoding the enzyme having fatty acid synthase activity comprises a nucleic acid sequence encoding an enzyme comprising an amino acid sequence as set forth in SEQ ID NO: 5 or 6. In some embodiments, the gene encoding an enzyme with fatty acid synthase activity comprises a nucleic acid sequence encoding an enzyme consisting of the amino acid sequence as set forth in SEQ ID NO:5 or 6.
[0103] Identification of additional enzymes that have or are predicted to have fatty acid synthase activity may be based on similarity or homology to one or more domains of a fatty acid synthase, such as, for example, the fatty acid synthase set forth in SEQ ID NO: 5 or 6. In some embodiments, enzymes for use in the modified cells and methods described herein may be identified based on similarity or homology to an activity domain, such as a catalytic domain, such as a catalytic domain associated with fatty acid synthase activity. In some embodiments, enzymes for use in the modified cells and methods described herein may have a relatively high level of sequence identity to a reference fatty acid synthase (e.g., a wild-type fatty acid synthase such as SEQ ID NO: 5) in the region of the catalytic domain, but a relatively lower level of sequence identity to the reference fatty acid synthase based on analysis of a longer portion of the enzyme or over the full length of the enzyme. In some embodiments, an enzyme for use in the modified cells and methods described herein has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity in the region of the catalytic domain of the enzyme relative to a reference fatty acid synthase (e.g., SEQ ID NO: 5).
[0104] In some embodiments, the enzymes for use in the modified cells and methods described herein have a relatively high level of sequence identity in the region of the catalytic domain of the enzyme compared to a reference fatty acid synthase (e.g., SEQ ID NO: 5 or 6), and a relatively low level of sequence identity to the reference fatty acid synthase based on analysis of a longer portion of the enzyme or over the full length of the enzyme. In some embodiments, the enzymes for use in the modified cells and methods described herein have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity, based on a portion of the enzyme or over the full length of the enzyme, relative to a reference fatty acid synthase (e.g., SEQ ID NO: 5 or 6).
[0105] This information can also be used to identify positions, e.g., corresponding positions, in other enzymes that have or are predicted to have fatty acid synthase activity. As will be apparent to one of skill in the art, amino acid substitutions at positions identified in one fatty acid synthase enzyme can also be made at corresponding amino acid positions in another fatty acid synthase enzyme. In such cases, one of the fatty acid synthase enzymes may be used as a reference enzyme. For example, as described herein, an amino acid substitution at position G1250 of FAS2 from Saccharomyces cerevisiae (SEQ ID NO: 5) has been shown to increase the production of ethyl hexanoate. Similar amino acid substitutions can be made at corresponding positions in other enzymes with fatty acid synthase activity using FAS2 as a reference (e.g., SEQ ID NO: 5). For example, amino acid substitutions can be made at corresponding positions in fatty acid synthases from another yeast species, another fungal species, another microorganism, or another eukaryote as described herein using FAS2 as a reference (e.g., SEQ ID NO: 5).
[0106] The fatty acid synthase variants described herein contain one or more amino acid substitutions at positions corresponding to reference fatty acid synthase.In some embodiments, the fatty acid synthase variants contain 1, 2, 3, 4, 5 or more amino acid substitutions at positions corresponding to reference fatty acid synthase.In some embodiments, the fatty acid synthase is a non-naturally occurring (for example, genetically modified) fatty acid synthase.In some embodiments, the fatty acid synthase does not have the amino acid sequence defined in SEQ ID NO:5.
[0107] Hexanoyl-CoA synthetase (HCS) enzyme In some embodiments, the genetically modified cells described herein contain a gene encoding an enzyme with hexanoyl-CoA synthetase (HCS) activity. In some embodiments, the gene is a heterologous gene. The hexanoyl-CoA synthetase (HCS) enzyme is an acyl-activating enzyme (AAE) that catalyzes the formation of hexanoyl-CoA from the substrate hexanoic acid and free coenzyme A (CoA). Without wishing to be bound by any particular theory, expression of hexanoyl-CoA synthetase during fermentation may reduce the final yield of hexanoic acid in the fermentation product or beverage. Hexanoyl-CoA is a substrate for the enzymatic reaction that forms ethyl hexanoate, and expression of hexanoyl-CoA synthetase during fermentation may further increase the final yield of ethyl hexanoate in the fermentation product or beverage. Genetically modified cells that express the hexanoyl-CoA synthetase enzyme may produce a fermentation product or beverage that has higher levels of the desired ethyl hexanoate and lower concentrations of the undesirable hexanoic acid compared to cells that do not express hexanoyl-CoA synthetase.
[0108] In some embodiments, the hexanoyl-CoA synthetase gene is from a plant. In some embodiments, the hexanoyl-CoA synthetase gene is from a Cannabis species. In some embodiments, the hexanoyl-CoA synthetase gene is from Cannabis sativa.
[0109] An exemplary HCS enzyme is CsAAE1 from Cannabis sativa, defined by accession number H9A1V3-1 and the amino acid sequence represented as SEQ ID NO:7. (SEQ ID NO: 7).
[0110] In some embodiments, the heterologous gene encodes an enzyme with hexanoyl-CoA synthetase activity, such that the enzyme reduces the level of hexanoic acid in the fermentation product or beverage. In some embodiments, the heterologous gene encodes an enzyme with hexanoyl-CoA synthetase activity, such that the enzyme increases the level of ethyl hexanoate in the fermentation product or beverage.
[0111] In some embodiments, the enzyme with hexanoyl-CoA synthetase activity has an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence as set forth in SEQ ID NO:7.
[0112] As used herein, when a percent identity or range thereof (e.g., at least, more, etc.) is specified, unless otherwise specified, the endpoints are intended to be encompassed, and a range (e.g., at least 70% identity) includes all ranges within the recited range (e.g., at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 1109%, at least 1111%, at least 112%, at least 113%, at least 114%, at least 115%, at least 116%, at least 117%, at least 118%, at least 119%, at least 120%, at least 121%, at least 122%, at least 123%, at least 124%, at least 125%, at least 126%, at least 127%, at least 128%, at least 129%, at least 130%, at least 131%, at least 132%, at least 133%, at least 134%, at least 135%, at least 136%, at "identity" includes at least 99.9%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identity), and all increments thereof (e.g., tenths of a percent (i.e., 0.1%), hundredths of a percent (i.e., 0.01%), etc.).
[0113] In some embodiments, the enzyme with hexanoyl-CoA synthetase activity comprises the amino acid sequence as set forth in SEQ ID NO: 7. In some embodiments, the enzyme with hexanoyl-CoA synthetase activity consists of the amino acid sequence as set forth in SEQ ID NO: 7.
[0114] In some embodiments, the gene encoding the enzyme having hexanoyl-CoA synthetase activity comprises a nucleic acid sequence encoding an enzyme comprising an amino acid sequence having at least 80% (e.g., at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9%) sequence identity to the sequence set forth in SEQ ID NO:7. In some embodiments, the gene encoding the enzyme with hexanoyl-CoA synthetase activity comprises a nucleic acid sequence encoding an enzyme comprising the amino acid sequence as set forth in SEQ ID NO:7. In some embodiments, the gene encoding the enzyme with hexanoyl-CoA synthetase activity comprises a nucleic acid sequence encoding an enzyme consisting of the amino acid sequence as set forth in SEQ ID NO:7.
[0115] Identification of additional enzymes that have hexanoyl-CoA synthetase activity or are predicted to have hexanoyl-CoA synthetase activity may be performed based on similarity or homology to one or more domains of a hexanoyl-CoA synthetase, such as the hexanoyl-CoA synthetase set forth in SEQ ID NO: 7. In some embodiments, enzymes for use in the modified cells and methods described herein may be identified based on similarity or homology to an activity domain, such as a catalytic domain, such as a catalytic domain associated with hexanoyl-CoA synthetase activity. In some embodiments, enzymes for use in the modified cells and methods described herein may have a relatively high level of sequence identity to a reference hexanoyl-CoA synthetase (e.g., a wild-type fatty acid synthase such as SEQ ID NO: 7) in the region of the catalytic domain, but a relatively lower level of sequence identity to the reference hexanoyl-CoA synthetase based on analysis of a longer portion of the enzyme or over the full length of the enzyme. In some embodiments, an enzyme for use in the modified cells and methods described herein has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity in the region of the catalytic domain of the enzyme relative to a reference hexanoyl-CoA synthetase (e.g., SEQ ID NO: 7).
[0116] In some embodiments, the enzymes for use in the modified cells and methods described herein have a relatively high level of sequence identity in the region of the catalytic domain of the enzyme compared to a reference hexanoyl-CoA synthetase (e.g., SEQ ID NO: 7), and a relatively low level of sequence identity to the reference hexanoyl-CoA synthetase based on analysis of a longer portion of the enzyme or over the full length of the enzyme. In some embodiments, the enzymes for use in the modified cells and methods described herein have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity, based on a portion of the enzyme or over the full length of the enzyme, relative to a reference hexanoyl-CoA synthetase (e.g., SEQ ID NO: 7).
[0117] General methods for enzyme modification As will also be apparent to those skilled in the art, the amino acid position number of a selected residue in an alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase may have a different amino acid position number in another alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase enzyme (e.g., a reference enzyme). Generally, methods known in the art may be used to identify corresponding positions in other beta-lyase enzymes, e.g., by aligning the amino acid sequences of two or more enzymes. Software programs and algorithms for aligning amino acid (or nucleotide) sequences are known in the art and readily available (e.g., Clustal Omega (Sievers et al. 2011)).
[0118] Variants of the alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase described herein may further contain one or more additional modifications that, for example, specifically alter a feature of the polypeptide unrelated to its desired physiological activity. Alternatively, or in addition, the alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase enzymes described herein may contain one or more mutations that modulate the expression and / or activity of the enzyme in a cell.
[0119] Mutations in nucleic acids encoding alcohol-O-acyltransferases, fatty acid synthases, and / or hexanoyl-CoA synthetase preferably preserve the amino acid reading frame of the coding sequence and preferably do not create regions in the nucleic acid that are likely to hybridize to form secondary structures, such as hairpins or loops, that may be detrimental to expression of the enzyme.
[0120] Mutations can be made by selecting amino acid substitutions in the nucleic acid encoding the polypeptide or by random mutagenesis of selected sites. As described herein, the variant polypeptide can be expressed and tested for one or more activities to determine whether the mutations provide a variant polypeptide with desired properties. Additional mutations can be made to the variant (or non-variant polypeptide) that are silent with respect to the amino acid sequence of the polypeptide but provide preferred codons for translation in a particular host (referred to as codon optimization). Preferred codons for translation of nucleic acids (e.g., nucleic acids in S. cerevisiae) are well known to those of skill in the art. Still other mutations can be made to non-coding sequences of a gene or cDNA clone to enhance polypeptide expression. The activity of an alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase (enzyme) variant can be tested by cloning the gene encoding the enzyme variant into an expression vector, introducing the vector into a suitable host cell, expressing the enzyme variant, and testing for the functional capability of the enzyme as disclosed herein.
[0121] Variants of the alcohol-O-acyltransferases, fatty acid synthases, and / or hexanoyl-CoA synthetases described herein may contain amino acid substitutions at one or more positions corresponding to the reference alcohol-O-acyltransferases, fatty acid synthases, and / or hexanoyl-CoA synthetases. In some embodiments, variants of the alcohol-O-acyltransferases, fatty acid synthases, and / or hexanoyl-CoA synthetases contain amino acid substitutions at one, two, three, four, five, or more positions corresponding to the reference alcohol-O-acyltransferases, fatty acid synthases, and / or hexanoyl-CoA synthetases. In some embodiments, the beta-lyase is a non-naturally occurring alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase, e.g., genetically modified.
[0122] In some embodiments, variants of alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase may also contain one or more amino acid substitutions that do not substantially affect the activity and / or structure of the alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase enzyme. Those skilled in the art will also recognize that conservative amino acid substitutions may be made to an enzyme to provide a functionally equivalent variant of the polypeptide, i.e., the variant retains the functional capability of the polypeptide. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution that does not alter characteristics such as the relative charge or size of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequences known to those skilled in the art, such as those found in references compiling such methods, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or Current Protocols in Molecular Biology, F.M.Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of polypeptides include conservative amino acid substitutions in the amino acid sequences of the proteins disclosed herein. Conservative amino acid substitutions include substitutions made from amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.
[0123] As will be appreciated by those skilled in the art, homologous genes encoding enzymes having alcohol-O-acyltransferase activity can be obtained from other species and identified by homology searches, for example, through protein BLAST searches available at the National Center for Biotechnology Information (NCBI) internet site (ncbi.nlm.nih.gov). By aligning the amino acid sequence of an enzyme with one or more reference enzymes and / or comparing the secondary or tertiary structure of a similar or homologous enzyme with one or more reference beta-lyases, corresponding amino acid residues in the similar or homologous enzymes can be determined, and amino acid residues for mutation in the similar or homologous enzymes can be determined.
[0124] The genes related to the present disclosure can be obtained from DNA (e.g., by PCR amplification) from any source of DNA containing the desired gene. In some embodiments, the genes related to the present invention are synthetic, e.g., produced in vitro by chemical synthesis. Any means of obtaining genes encoding the enzymes described herein is compatible with the modified cells and methods described herein.
[0125] The disclosure provided herein involves the recombinant expression of genes encoding enzymes having alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase activity, functional modifications and variants of the above enzymes, and related uses. Homologs and alleles of the nucleic acids related to the present invention can be identified by conventional techniques. Also encompassed by the present invention are nucleic acids that hybridize to the nucleic acids described herein under stringent conditions. The term "stringent conditions" as used herein refers to parameters well known in the art. Nucleic acid hybridization parameters can also be found in references compiling such methods, for example, Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or Current Protocols in Molecular Biology, F.M.A.usubel, et al., eds., John Wiley & Sons, Inc., New York.
[0126] Other conditions, reagents, etc. can be used, but will result in a similar degree of stringency. Those skilled in the art are familiar with such conditions, and therefore will not be given here. However, it is understood that those skilled in the art will be able to manipulate the conditions (for example, by using lower stringency conditions) in a manner that allows for the unambiguous identification of homologs and alleles of the nucleic acids of the invention. Those skilled in the art are also familiar with methodologies for screening cells and libraries for the expression of such molecules, which are then routinely isolated, followed by the isolation and sequencing of the relevant nucleic acid molecules.
[0127] The present invention also encompasses degenerate nucleic acids, which include codons that substitute for those present in the native material. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT, and AGC. Each of the six codons is equivalent for the purpose of encoding a serine residue. Thus, it will be apparent to those skilled in the art that any of the nucleotide triplets encoding serine may be employed to direct the protein synthesis machinery to incorporate the serine residue into a growing polypeptide in vitro or in vivo. Similarly, nucleotide sequence triplets encoding other amino acid residues include, but are not limited to, the following: CCA, CCC, CCG, and CCT (proline codons); CGA, CGC, CGG, CGT, AGA, and AGG (arginine codons); ACA, ACC, ACG, and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC, and ATT (isoleucine codons). Other amino acid residues may similarly be encoded by multiple nucleotide sequences. Thus, the present invention encompasses degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code. The present invention also encompasses codon optimization to match optimal codon usage in the host cell.
[0128] The present invention also provides modified nucleic acid molecules that include additions, substitutions, and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules, and / or the polypeptides they encode, retain at least one activity or function (such as enzymatic activity) of the unmodified nucleic acid molecule and / or polypeptide. In some embodiments, the modified nucleic acid molecule encodes a modified polypeptide, preferably a polypeptide with conservative amino acid substitutions as described elsewhere herein. The modified nucleic acid molecule is structurally related to the unmodified nucleic acid molecule, and in preferred embodiments, is sufficiently structurally related to the unmodified nucleic acid molecule, such that the modified and unmodified nucleic acid molecules can hybridize under stringent conditions known to those of skill in the art.
[0129] For example, modified nucleic acid molecules encoding polypeptides with a single amino acid change can be prepared. Each of these nucleic acid molecules can have one, two, or three nucleotide substitutions, excluding nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Similarly, modified nucleic acid molecules encoding polypeptides with two amino acid changes (e.g., having two to six nucleotide changes) can also be prepared. Numerous modified nucleic acid molecules such as these (e.g., including nucleotide substitutions in codons encoding two and three, two and four, two and five, two and six, etc. amino acids) will be readily envisioned by those skilled in the art. In the above example, each combination of two amino acids is encompassed in the series of modified nucleic acid molecules, as well as all nucleotide substitutions encoding amino acid substitutions. Additional nucleic acid molecules encoding polypeptides with additional substitutions (i.e., three or more), additions, or deletions (e.g., by introducing a stop codon or splice site(s)) can also be prepared and are encompassed by the present invention, as will be readily envisioned by those skilled in the art. Any of the above nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relationship or activity with the nucleic acids and / or polypeptides disclosed herein.
[0130] In some embodiments, one or more of the genes related to the present invention are expressed in a recombinant expression vector. As used herein, a "vector" refers to any of a number of nucleic acids into which a desired sequence(s) may be inserted by restriction and ligation for transport between different production environments or for expression in a host cell. Vectors are typically composed of DNA, although RNA vectors are also available. Vectors include, but are not limited to, the following: plasmids, fosmids, phagemids, viral genomes, and artificial chromosomes.
[0131] A cloning vector is a vector that can replicate autonomously or that integrates into the genome of a host cell. In the case of a plasmid, replication of the desired sequence may occur multiple times as the plasmid increases in copy number within the host cell (such as a host bacterium), or only once per host before the host reproduces by mitosis. In the case of a phage, replication may occur actively during the lytic phase or passively during the lysogenic phase.
[0132] An expression vector is a vector into which a desired DNA sequence may be inserted such that it is operably linked to regulatory sequences by restriction and ligation and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in identifying cells that have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins that increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes encoding enzymes whose activities can be detected by standard assays known in the art (e.g., β-galactosidase, luciferase, or alkaline phosphatase), and genes that visibly affect the phenotype of transformed or transfected cells, hosts, colonies, or plaques (e.g., green fluorescent protein). Preferred vectors are capable of autonomous replication and expression of structural gene products present in the DNA segment to which they are operably linked.
[0133] As used herein, a coding sequence and a regulatory sequence are said to be "operably" associated or operably linked when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. When it is desired that the coding sequence be translated into a functional protein, two DNA sequences are said to be operably associated or operably linked if induction of a promoter in the 5' regulatory sequences results in transcription of the coding sequence, and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region to direct transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into protein. Thus, a promoter region would be operably linked to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence, such that the resulting transcript could be translated into the desired protein or polypeptide.
[0134] When a nucleic acid molecule encoding any of the enzymes of the present disclosure is expressed in a cell, various transcription control sequences (e.g., promoter / enhancer sequences) can be used to direct its expression. The promoter can be the native promoter, i.e., the promoter of the gene in its native context, which provides normal regulation of expression of the gene. In some embodiments, the promoter can be constitutive, i.e., the promoter is not regulated to allow continuous transcription of its associated gene (e.g., an enzyme having alcohol-O-acyltransferase, fatty acid synthase, or hexanoyl-CoA synthetase activity). Various conditional promoters can also be used, such as promoters controlled by the presence or absence of a molecule.
[0135] The precise nature of regulatory sequences required for gene expression may vary between species or cell types, but generally include, as necessary, 5' non-transcribed and 5' non-translated sequences involved in initiation of transcription and translation, respectively, such as the TATA box, capping sequence, CAAT sequence, etc. In particular, such 5' non-transcribed regulatory sequences will include a promoter region containing a promoter sequence for transcriptional control of an operably linked gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences, as desired. Vectors of the invention may optionally include 5' leader or signal sequences. The selection and design of an appropriate vector is within the ability and discretion of one skilled in the art.
[0136] Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press, 2012. Cells are genetically modified by the introduction of heterologous DNA (RNA) into the cell. The heterologous DNA (RNA) is placed under operable control of transcriptional elements, allowing for expression of the heterologous DNA in the host cell. As will be appreciated by those skilled in the art, any of the enzymes described herein can also be expressed in other yeast cells, including yeast strains used to produce wine, mead, sake, apple cider, etc.
[0137] Nucleic acid molecules encoding the enzymes of the present disclosure can be introduced into a cell(s) using methods and techniques standard in the art. For example, the nucleic acid molecules can be introduced by standard protocols such as chemical transformation and transformation, including electroporation, transduction, biolistics, etc. Expressing nucleic acid molecules encoding the enzymes of the claimed invention may also be achieved by integrating the nucleic acid molecules into the genome.
[0138] Genetic integration can be achieved either by incorporation of the new nucleic acid into the genome of the yeast cell, or by transient or stable maintenance of the new nucleic acid as an episomal element. In eukaryotic cells, permanent, heritable genetic changes are generally achieved by introduction of DNA into the genome of the cell.
[0139] A heterologous gene may also include various transcription elements required for expression of the encoded gene product (e.g., an enzyme having an alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase). For example, in some embodiments, the gene may include a promoter. In some embodiments, the promoter may be operably linked to the gene. In some embodiments, the promoter is an inducible promoter. In some embodiments, the promoter is active during a specific stage of the fermentation process. For example, in some embodiments, peak expression from the promoter is during an early stage of the fermentation process, e.g., before >50% of the fermentable sugars are consumed. In some embodiments, peak expression from the promoter is during a later stage of the fermentation process, e.g., after 50% of the fermentable sugars are consumed.
[0140] Medium conditions change over the course of the fermentation process; for example, as sugar sources and oxygen become depleted, nutrient and oxygen availability tends to decrease over time during fermentation. In addition, the presence of other factors, such as products produced by cellular metabolism, increases. In some embodiments, the promoter is regulated by one or more conditions in the fermentation process, such as the presence or absence of one or more factors. In some embodiments, the promoter is regulated by hypoxic conditions. Examples of promoters of hypoxia-activated genes are known in the art. For example, see Zitomer et al., Kidney Int. (1997) 51(2):507-13; Gonzalez Siso et al., Biotechnol. Letters (2012) 34:2161-2173.
[0141] In some embodiments, the promoter is a constitutive promoter. Examples of constitutive promoters for use in yeast cells are known in the art and will be apparent to those skilled in the art. In some embodiments, the promoter is a yeast promoter, e.g., a native promoter from the yeast cell in which the heterologous or exogenous gene is expressed.
[0142] In some embodiments, the promoter is a HEM13 promoter (pHEM13), an SPG1 promoter (pSPG1), a PRB1 promoter (pPRB1), a QCR10 (pQCR10), a PGK1 promoter (pPGK1), an OLE1 promoter (pOLE1), an ERG25 promoter (pERG25), or an HHF2 promoter (pHHF2).
[0143] An exemplary HEM13 promoter is pHEM13 from S. cerevisiae, which is defined by the nucleotide sequence set forth as SEQ ID NO:8. (SEQ ID NO: 8).
[0144] An exemplary SPG1 promoter is pSPG1 from S. cerevisiae, defined by the nucleotide sequence set forth as SEQ ID NO:9. (SEQ ID NO: 9).
[0145] An exemplary PRB1 promoter is pPRB1 from S. cerevisiae, defined by the nucleotide sequence set forth as SEQ ID NO:10. (SEQ ID NO: 10).
[0146] An exemplary QCR10 promoter is pQCR10 from S. cerevisiae, defined by the nucleotide sequence represented as SEQ ID NO:22. GAGAGCTGGCCAAAAAGAGGGCCGAAGACGGCGTTGAATTTCATTCAAAACTATTTAGAAGGGCAGAGCCAGGTGAGGATTTAGATTATTATATTTACAAGCACATCCCTGAAGGGACCGACAAGCATGAAGAACAGATCAGGAGCATTTTGGAAACTGCCCCGATTTTACCAGGACAGGCATTCACTGAAAAATTTTCTATTCCGGCTTATAAAAAGCATGGAATCCAAAAGAATTAGGCTTCTCATTCTATTTTAATTATACTAGTACGATTTCTCACTCTGTAATTTAATATCAGTGTAATATGCACCTAGTTATGGGTAGTTTTTGCTAACGTTACGAGCCGCGAAACTGTCCTCAATCTTCACCACTACCTCTAATGACTGAAGAATGCTATGCGATATAACGCTGCCGCACTTTGAATATATACTTATATTTACATAGTTTTCAAGTGCGTATTACTATTGCAAAGTAGTATTTTGTCACGTGATTTTGATCCAATTAAAACTAAATATGGTTCAACCCGTTGTTTCCGCATCAAAAAACCATACCATTTATCAAGGGGACGGGATATATCACATAACAGTTTGAATGCATAATTTGTTATAGATATCTTCTGGAATAATCTTCACAGCAAAAGCGCAAGTCGAATAATATATCGATAAATACAATCCATAAGACTTAAAACTAACCTCA(SEQ ID NO: 22).
[0147] Genetically modified yeast cells Aspects of the present disclosure relate to genetically modified yeast cells (modified cells) and the use of such modified cells in methods for producing fermentation products (e.g., fermented beverages) and methods for producing ethanol. The genetically modified yeast cells described herein are genetically modified with a heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity, an exogenous gene encoding an enzyme with fatty acid synthase activity, and / or a heterologous gene encoding an enzyme with hexanoyl-CoA synthetase activity.
[0148] The terms "genetically modified cell," "genetically modified yeast cell," and "modified cell," which may be used interchangeably herein, refer to eukaryotic cells (e.g., yeast cells that have been or will soon be modified by the introduction of a heterologous gene). These terms (e.g., modified cell) encompass the progeny of an original cell that has been genetically modified by the introduction of a heterologous gene. It will be understood by those skilled in the art that the progeny of a single cell may not necessarily be completely identical in morphology or genomic or total nucleic acid complement to the original parent due to mutations (i.e., natural, accidental, or deliberate alterations of the nucleic acid of the modified cell).
[0149] Yeast cells for use in the methods described herein are preferably capable of fermenting a sugar source (e.g., fermentable sugars) to produce ethanol (ethyl alcohol) and carbon dioxide. In some embodiments, the yeast cells are of the genus Saccharomyces. The genus Saccharomyces encompasses approximately 500 distinct species, many of which are used in food production. One exemplary species is Saccharomyces cerevisiae (S. cerevisiae), which is commonly referred to as "brewer's yeast" or "baker's yeast" and is used in the production of wine, bread, and beer, among other products. Other members of the Saccharomyces genus include, but are not limited to, the wild yeast Saccharomyces paradoxus, which is closely related to S. cerevisiae; Saccharomyces bayanus, Saccharomyces pastorianus, Saccharomyces carlsbergensis, Saccharomyces uvarum, Saccharomyces cerevisiae var boulardii, and Saccharomyces eubayanus. In some embodiments, the yeast is Saccharomyces cerevisiae (S. cerevisiae).
[0150] Saccharomyces species may be haploid (i.e., having a single set of chromosomes), diploid (i.e., having a paired set of chromosomes), or polyploid (i.e., having or containing more than two sets of homologous chromosomes). Saccharomyces species used (e.g., for beer brewing) are typically classified into two groups: top-fermenting ale strains (e.g., S. cerevisiae) and bottom-fermenting lager strains (e.g., S. pastorianus, S. carlsbergensis, S. uvarum). These characterizations reflect their separation characteristics in open-top square fermenters, as well as often other characteristics such as preferred fermentation temperatures and achieved alcohol concentrations.
[0151] While beer brewing and wine production have traditionally focused on the use of S. cerevisiae strains, other yeast genera are also appreciated in the production of fermented beverages. In some embodiments, the yeast cell belongs to a non-Saccharomyces genus. See, for example, Crauwels et al. Brewing Science (2015) 68:110-121; Esteves et al. Microorganisms (2019) 7(11):478. In some embodiments, the yeast cell is of the genus Kloeckera, Candida, Starmerella, Hanseniaspora, Kluyveromyces / Lachance, Metschnikowia, Saccharomycodes, Zygosaccharomyce, Dekkera (also called Brettanomyces), Wickerhamomyces, or Torulaspora. Examples of non-Saccharomyces yeasts include, but are not limited to, Hanseniaspora uvarum, Hanseniaspora guillermondii, Hanseniaspora vinae, Metschnikowia pulcherrima, Kluyveromyces / Lachancea thermotolerans, Starmerella bacillaris (previously referred to as Candida stellata / Candida zemplinina), Saccharomycodes ludwigii, Zygosaccharomyces rouxii, Dekkera bruxellensis, Dekkera anomala, Brettanomyces custersianus, Brettanomyces naardenensis, Brettanomyces nanus, Wickerhamomyces anomalus, and Torulaspora delbrueckii.
[0152] In some embodiments, the methods described herein involve the use of more than one genetically modified yeast. For example, in some embodiments, the methods may involve the use of more than one genetically modified yeast belonging to the genus Saccharomyces. In some embodiments, the methods may involve the use of more than one genetically modified yeast belonging to a non-Saccharomyces genus. In some embodiments, the methods may involve the use of more than one genetically modified yeast belonging to the genus Saccharomyces and one genetically modified yeast belonging to a non-Saccharomyces genus. Alternatively or additionally, any of the methods described herein may involve the use of one or more genetically modified yeast and one or more genetically unmodified (wild-type) yeast.
[0153] In some embodiments, the yeast is a hybrid strain. As will be apparent to those skilled in the art, the term "hybrid strain" of yeast refers to a yeast strain resulting from the mating of two different yeast strains, for example, to obtain one or more desired characteristics. For example, a hybrid strain may be the result of mating two different yeast strains belonging to the same genus or species. In some embodiments, a hybrid strain is the result of mating a Saccharomyces cerevisiae strain with a Saccharomyces eubayanus strain. For example, see Krogerus et al. Microbial Cell Factories (2017) 16:66.
[0154] In some embodiments, the yeast strain is a wild yeast strain, such as a yeast strain isolated from a natural source and subsequently propagated. Alternatively, in some embodiments, the yeast strain is a domesticated yeast strain. Environmentally adapted yeast strains have been subject to human selection and breeding for desirable characteristics.
[0155] In some embodiments, genetically modified yeast cells may be used in a symbiotic matrix with strains and used to produce fermented beverages such as kombucha, kefir, and ginger beer. For example, Saccharomyces fragilis is an integral part of kefir cultures and is grown on lactose contained in whey.
[0156] Methods for genetically modifying yeast cells are known in the art. In some embodiments, the yeast cells are diploid and one copy of a heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity as described herein is introduced into the yeast genome.
[0157] In some embodiments, the yeast cells are diploid, and one copy of a heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity as described herein is introduced into both copies of the yeast genome. In some embodiments, the copies of the heterologous gene are identical. In some embodiments, the copies of the heterologous gene are not identical, but the gene encodes an enzyme with the same alcohol-O-acyltransferase activity. In some embodiments, the copies of the heterologous gene are not identical, and the gene encodes a different enzyme (e.g., a mutant, variant, or fragment thereof) with alcohol-O-acyltransferase activity.
[0158] In some embodiments, the yeast cell is diploid, and one copy of a gene encoding an enzyme with fatty acid synthase activity as described herein is introduced into both copies of the yeast genome. In some embodiments, the copies of the gene encoding the enzyme with fatty acid synthase activity are identical. In some embodiments, the copies of the gene encoding the enzyme with fatty acid synthase activity are not identical, but the genes encode enzymes with the same fatty acid synthase activity. In some embodiments, the copies of the gene encoding the enzyme with fatty acid synthase activity are not identical, and the genes encode enzymes with different fatty acid synthase activities (e.g., mutants, variants, or fragments thereof). In some embodiments, the cell contains a gene encoding an enzyme with fatty acid synthase activity, referred to as the endogenous gene, and also contains a second gene encoding an enzyme with fatty acid synthase activity, which may be an enzyme with the same or a different fatty acid synthase activity as that encoded by the endogenous gene.
[0159] In some embodiments, the yeast cell is diploid and one copy of a heterologous gene encoding an enzyme with hexanoyl-CoA synthetase activity as described herein is introduced into both copies of the yeast genome. In some embodiments, the copies of the heterologous gene are identical. In some embodiments, the copies of the heterologous gene are not identical, but the genes encode the same enzyme with hexanoyl-CoA synthetase activity. In some embodiments, the copies of the heterologous gene are not identical, and the genes encode enzymes (e.g., mutants, variants, or fragments thereof) with different hexanoyl-CoA synthetase activities.
[0160] In some embodiments, the yeast cell is tetraploid. A tetraploid yeast cell is a cell that maintains four complete sets of chromosomes (i.e., four copies of a complete set of chromosomes). In some embodiments, the yeast cell is tetraploid and a copy of a heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity as described herein is introduced into at least one copy of the genome. In some embodiments, the yeast cell is tetraploid and a copy of a heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity as described herein is introduced into more than one copy of the genome. In some embodiments, the yeast cell is tetraploid and a copy of a heterologous gene encoding an enzyme with alcohol-O-acyltransferase activity as described herein is introduced into all four copies of the genome. In some embodiments, the copies of the heterologous gene are identical. In some embodiments, the copies of the heterologous gene are not identical, but the gene encodes an enzyme with the same alcohol-O-acyltransferase activity. In some embodiments, the copies of the heterologous gene are not identical, and the gene encodes different enzymes (eg, mutants, variants, fragments thereof) having alcohol-O-acyltransferase activity.
[0161] In some embodiments, the yeast cell is tetraploid and a copy of a gene encoding an enzyme with fatty acid synthase activity as described herein is introduced into at least one copy of the genome. In some embodiments, the yeast cell is tetraploid and a copy of a gene encoding an enzyme with fatty acid synthase activity as described herein is introduced into more than one copy of the genome. In some embodiments, the yeast cell is tetraploid and a copy of a gene encoding an enzyme with fatty acid synthase activity as described herein is introduced into all four copies of the genome. In some embodiments, the copies of the gene encoding an enzyme with fatty acid synthase activity are identical. In some embodiments, the copies of the gene encoding an enzyme with fatty acid synthase activity are not identical, but the genes encode enzymes with the same fatty acid synthase activity. In some embodiments, the copies of the gene encoding an enzyme with fatty acid synthase activity are not identical, and the genes encode enzymes (e.g., mutants, variants, or fragments thereof) with different fatty acid synthase activities. In some embodiments, the cell contains a gene encoding an enzyme with fatty acid synthase activity, referred to as the endogenous gene, and also contains one or more additional copies of a gene encoding an enzyme with fatty acid synthase activity, which may be the same or a different enzyme with fatty acid synthase activity as that encoded by the endogenous gene.
[0162] In some embodiments, the yeast cell is tetraploid and a copy of a heterologous gene encoding an enzyme with hexanoyl-CoA synthetase activity as described herein is introduced into at least one copy of the genome. In some embodiments, the yeast cell is tetraploid and a copy of a heterologous gene encoding an enzyme with hexanoyl-CoA synthetase activity as described herein is introduced into more than one copy of the genome. In some embodiments, the yeast cell is tetraploid and a copy of a heterologous gene encoding an enzyme with hexanoyl-CoA synthetase activity as described herein is introduced into all four copies of the genome. In some embodiments, the copies of the heterologous gene are identical. In some embodiments, the copies of the heterologous gene are not identical, but the genes encode the same enzyme with hexanoyl-CoA synthetase activity. In some embodiments, the copies of the heterologous gene are not identical, and the genes encode enzymes (e.g., mutants, variants, or fragments thereof) with different hexanoyl-CoA synthetase activities.
[0163] In some embodiments, the growth rate of the modified cells is substantially unimpaired compared to wild-type yeast cells that do not contain the first heterologous gene and the second exogenous gene. Methods for measuring and comparing the growth rates of two cells will be known to those of skill in the art. Non-limiting examples of growth rates that can be measured and compared between two types of cells include replication rate, budding rate, colony forming units (CFU) produced per unit time, and the amount of fermentable sugars in the medium reduced per unit time. The growth rate of the modified cells is "substantially unimpaired" compared to wild-type cells if the growth rate, as measured, is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100% of the growth rate of the wild-type cells.
[0164] Strains of yeast cells that may be used in the methods described herein will be known to those skilled in the art, and include yeast strains used to brew the desired fermented beverage, as well as commercially available yeast strains. Examples of common beer strains include, but are not limited to, American ale strains, Belgian ale strains, British ale strains, Belgian lambic / sour ale strains, Barleywine / Imperial Stout strains, India Pale Ale strains, Brown Ale strains, Kolsch and Altbier strains, Stout and Porter strains, and Wheat beer strains.
[0165] Non-limiting examples of yeast strains for use in the genetically modified cells and methods described herein include Wyeast American Ale 1056, Wyeast American Ale II 1272, Wyeast Denny's Favorite 50 1450, Wyeast Northwest Ale 1332, Wyeast Ringwood Ale 1187, Siebel Inst. American Ale BRY 96, White Labs American Ale Yeast Blend WLP060, White Labs California Ale V WLP051, White Labs California Ale WLP001, White Labs Old Sonoma Ale WLP076, White Labs Pacific Ale WLP041, White Labs East Coast Ale WLP008, White Labs East Midlands Ale WLP039, White Labs San Diego Super Yeast WLP090, White Labs San Francisco Lager WLP810, White Labs Neutral Grain WLP078, Lallemand American West Coast Ale BRY-97, Lallemand CBC-1(Cask and Bottle Conditioning), Brewferm Top, Coopers Pure Brewers' Yeast, Fermentis US-05, Real Brewers Yeast Lucky #7, Muntons Premium Gold, Muntons Standard Yeast, East Coast Yeast Northeast Ale ECY29, East Coast Yeast Old Newark Ale ECY10, East Coast Yeast Old Newark Beer ECY12, Fermentis Safale US-05, Fermentis Safbrew T-58, Real Brewers Yeast The One, Mangrove Jack US West CoastYeast、Mangrove Jack Workhorse Beer Yeast、Lallemand Abbaye Belgian Ale、White Labs Abbey IV WLP540、White Labs American Farmhouse Blend WLP670、White Labs Antwerp Ale WLP515、East Coast Yeast Belgian Abbaye ECY09、White Labs Belgian Ale WLP550、Mangrove Jack Belgian Ale Yeast、Wyeast Belgian Dark Ale 3822-PC、Wyeast Belgian Saison 3724、White Labs Belgian Saison I WLP565、White Labs Belgian Saison II WLP566、White Labs Belgian Saison III WLP585、Wyeast Belgian Schelde Ale 3655-PC、Wyeast Belgian Stout 1581-PC、White Labs Belgian Style Ale Yeast Blend WLP575、White Labs Belgian Style Saison Ale Blend WLP568、East Coast Yeast Belgian White ECY11、Lallemand Belle Saison、Wyeast Biere de Garde 3725-PC、White Labs Brettanomyces Bruxellensis Trois Vrai WLP648、Brewferm Top、Wyeast Canadian / Belgian Ale 3864-PC、Lallemand CBC-1(Cask and Bottle Conditioning)、Wyeast Farmhouse Ale 3726-PC、East Coast Yeast Farmhouse Brett ECY03、Wyeast Flanders Golden Ale 3739-PC、White Labs Flemish Ale Blend WLP665、White Labs French AleWLP072、Wyeast French Saison 3711、Wyeast Leuven Pale Ale 3538-PC、Fermentis Safbrew T-58、East Coast Yeast Saison Brasserie Blend ECY08、East Coast Yeast Saison Single-Strain ECY14、Real Brewers Yeast The Monk、Siebel Inst. Trappist Ale BRY 204、East Coast Yeast Trappist Ale ECY13、White Labs Trappist Ale WLP500、Wyeast Trappist Blend 3789-PC、Wyeast British Ale 1098、Wyeast British Ale II 1335、Wyeast British Cask Ale 1026-PC、Wyeast English Special Bitter 1768-PC、Wyeast Irish Ale 1084、Wyeast London Ale 1028、Wyeast London Ale III 1318、Wyeast London ESB Ale 1968、Wyeast Ringwood Ale 1187、Wyeast Thames Valley Ale 1275、Wyeast Thames Valley Ale II 1882-PC、Wyeast West Yorkshire Ale 1469、Wyeast Whitbread Ale 1099、Mangrove Jack British Ale Yeast、Mangrove Jack Burton Union Yeast、Mangrove Jack Workhorse Beer Yeast、East Coast Yeast British Mild Ale ECY18、East Coast Yeast Northeast Ale ECY29、East Coast Yeast Burton Union ECY17、East Coast Yeast Old Newark Ale ECY10、White Labs Bedford British Ale WLP006、WhiteLabs British Ale WLP005、White Labs Burton Ale WLP023、White Labs East Midlands Ale WLP039、White Labs English Ale Blend WLP085、White Labs English Ale WLP002、White Labs Essex Ale Yeast WLP022、White Labs Irish Ale WLP004、White Labs London Ale WLP013、White Labs Manchester Ale WLP038、White Labs Old Sonoma Ale WLP076、White Labs San Diego Super Yeast WLP090、White Labs Whitbread Ale WLP017、White Labs North Yorkshire Ale WLP037、Coopers Pure Brewers' Yeast、Siebel Inst. English Ale BRY 264、Muntons Premium Gold、Muntons Standard Yeast、Lallemand Nottingham、Fermentis Safale S-04、Fermentis Safbrew T-58、Lallemand Windsor(British Ale)、Real Brewers Yeast Ye Olde English、Brewferm Top、White Labs American Whiskey WLP065、White Labs Dry English Ale WLP007、White Labs Edinburgh Ale WLP028、Fermentis Safbrew S-33、Wyeast Scottish Ale 1728、East Coast Yeast Scottish Heavy ECY07、White Labs Super High Gravity WLP099、White Labs Whitbread Ale WLP017、Wyeast Belgian Lambic Blend 3278、Wyeast Belgian Schelde Ale3655-PC、Wyeast Berliner-Weisse Blend 3191-PC、Wyeast Brettanomyces Bruxellensis 5112、Wyeast Brettanomyces Lambicus 5526、Wyeast Lactobacillus 5335、Wyeast Pediococcus Cerevisiae 5733、Wyeast Roeselare Ale Blend 3763、Wyeast Trappist Blend 3789-Pc、White Labs Belgian Sour Mix Wlp655、White Labs Berliner Weisse Blend Wlp630、White Labs Saccharomyces “Bruxellensis”Trois Wlp644、White Labs Brettanomyces Bruxellensis Wlp650、White Labs Brettanomyces Claussenii Wlp645、White Labs Brettanomyces Lambicus Wlp653、White Labs Flemish Ale Blend Wlp665、East Coast Yeast Berliner Blend Ecy06、East Coast Yeast Brett Anomala Ecy04、East Coast Yeast Brett Bruxelensis Ecy05、East Coast Yeast Brett Custersianus Ecy19、East Coast Yeast Brett Nanus Ecy16、Strain #2、East Coast Yeast BugCounty ECY20、East Coast Yeast BugFarm ECY01、East Coast Yeast Farmhouse Brett ECY03、East Coast Yeast Flemish Ale ECY02、East Coast Yeast Oud Brune ECY23、Wyeast American Ale 1056、Siebel Inst. American Ale BRY 96、White Labs American Ale YeastBlend WLP060、White Labs Bourbon Yeast WLP070、White Labs California Ale V WLP051、White Labs California Ale WLP001、White Labs Dry English ale WLP007、White Labs East Coast Ale WLP008、White Labs Neutral Grain WLP078、White Labs Super High Gravity WLP099、White Labs Tennessee WLP050、Fermentis US-05、Real Brewers Yeast Lucky #7、Fermentis Safbrew S-33、East Coast Yeast Scottish Heavy ECY07、Lallemand Windsor(British Ale)、Wyeast American Ale 1056、Wyeast American Ale II 1272、Wyeast British Ale 1098、Wyeast British Ale II 1335、Wyeast Denny's Favorite 50 1450、Wyeast London Ale 1028、Wyeast London Ale III 1318、Wyeast London ESB Ale 1968、Wyeast Northwest Ale 1332、Wyeast Ringwood Ale 1187、Siebel Inst. American Ale BRY 96、White Labs American Ale Yeast Blend WLP060、White Labs Bedford British Ale WLP006、White Labs British Ale WLP005、White Labs Burton Ale WLP023、White Labs California Ale V WLP051、White Labs California Ale WLP001、White Labs East Coast Ale WLP008、White Labs English Ale WLP002、White Labs LondonAle WLP013、White Labs Essex Ale Yeast WLP022、White Labs Pacific Ale WLP041、White Labs San Diego Super Yeast WLP090、White Labs Whitbread Ale WLP017、Brewferm Top、Mangrove Jack Burton Union Yeast、Mangrove Jack US West Coast Yeast、Mangrove Jack Workhorse Beer Yeast、Coopers Pure Brewers' Yeast、Fermentis US-05、Fermentis Safale S-04、Fermentis Safbrew T-58、Real Brewers Yeast Lucky #7、Real Brewers Yeast The One、Muntons Premium Gold、Muntons Standard Yeast、East Coast Yeast Northeast Ale ECY29、Lallemand Nottingham、Lallemand Windsor(British Ale)、Wyeast American Ale 1056、Wyeast American Ale II 1272、Wyeast British Ale 1098、Wyeast British Ale II 1335、Wyeast Thames Valley Ale 1275、Wyeast Thames Valley Ale II 1882-PC、Wyeast West Yorkshire Ale 1469、Wyeast Whitbread Ale 1099、Wyeast British Cask Ale 1026-PC、Wyeast English Special Bitter 1768-PC、Wyeast London Ale 1028、Wyeast London Ale III 1318、Wyeast London ESB Ale 1968、Wyeast Northwest Ale 1332、Wyeast Ringwood Ale 1187、White Labs American Ale Yeast BlendWLP060、White Labs British Ale WLP005、White Labs Bedford British Ale WLP006、White Labs British Ale WLP005、White Labs Burton Ale WLP023、White Labs California Ale V WLP051、White Labs California Ale WLP001、White Labs East Coast Ale WLP008、White Labs English Ale WLP002、White Labs Essex Ale Yeast WLP022、White Labs French Ale WLP072、White Labs London Ale WLP013、White Labs Pacific Ale WLP041、White Labs Whitbread Ale WLP017、Brewferm Top、East Coast Yeast British Mild Ale ECY18、Coopers Pure Brewers' Yeast、Muntons Premium Gold、Muntons Standard Yeast、Mangrove Jack Newcastle Dark Ale Yeast、Lallemand CBC-1(Cask and Bottle Conditioning)、Lallemand Nottingham、Lallemand Windsor(British Ale)、Fermentis Safale S-04、Fermentis US-05、Siebel Inst. American Ale BRY 96、Wyeast American Wheat 1010、Wyeast German Ale 1007、Wyeast Koelsch 2565、Wyeast Kolsch II 2575-PC、White Labs Belgian Lager WLP815、White Labs Dusseldorf Alt WLP036、White Labs European Ale WLP011、White Labs German Ale / Koelsch WLP029、East Coast YeastKoelschbier ECY21、Mangrove Jack Workhorse Beer Yeast、Siebel Inst. Alt Ale BRY 144、Wyeast American Ale 1056、Wyeast American Ale II 1272、Wyeast British Ale 1098、Wyeast British Ale II 1335、Wyeast Denny's Favorite 50 1450、Wyeast English Special Bitter 1768-PC、Wyeast Irish Ale 1084、Wyeast London Ale 1028、Wyeast London Ale III 1318、Wyeast London ESB Ale 1968、Wyeast Northwest Ale 1332、Wyeast Ringwood Ale 1187、Wyeast Thames Valley Ale 1275、Wyeast Thames Valley Ale II 1882-PC、Wyeast West Yorkshire Ale 1469、Wyeast Whitbread Ale 1099、White Labs American Ale Yeast Blend WLP060、White Labs Bedford British Ale WLP006、White Labs British Ale WLP005、White Labs Burton Ale WLP023、White Labs California Ale V WLP051、White Labs California Ale WLP001、White Labs East Coast Ale WLP008、White Labs East Midlands Ale WLP039、White Labs English Ale WLP002、White Labs Essex Ale Yeast WLP022、White Labs Irish Ale WLP004、White Labs London Ale WLP013、White Labs Old Sonoma Ale WLP076、White Labs Pacific Ale WLP041、White LabsWhitbread Ale WLP017、Coopers Pure Brewers' Yeast、Fermentis US-05、Muntons Premium Gold、Muntons Standard Yeast、Fermentis Safale S-04、Lallemand Nottingham、Lallemand Windsor(British Ale)、Siebel Inst. American Ale BRY 96、White Labs American Hefeweizen Ale 320、White Labs Bavarian Weizen Ale 351、White Labs Belgian Wit Ale 400、White Labs Belgian Wit Ale II 410、White Labs Hefeweizen Ale 300、White Labs Hefeweizen IV Ale 380、Wyeast American Wheat 1010、Wyeast Bavarian Wheat 3638、Wyeast Bavarian Wheat Blend 3056、Wyeast Belgian Ardennes 3522、Wyeast Belgian Wheat 3942、Wyeast Belgian Witbier 3944、Wyeast Canadian / Belgian Ale 3864-PC、Wyeast Forbidden Fruit Yeast 3463、Wyeast German Wheat 3333、Wyeast Weihenstephan Weizen 3068、Siebel Institute Bavarian Weizen BRY 235、Fermentis Safbrew WB-06、Mangrove Jack Bavarian Wheat、Lallemand Munich(German Wheat Beer)、Brewferm Blanche、Brewferm Lager、East Coast Yeast In some embodiments, the yeast is S. cerevisiae strain WLP001 California Ale (which may also be referred to as "CA01").
[0166] In some embodiments, the yeast strain for use in the genetically modified cells and methods described herein is a wine yeast strain. Examples of yeast strains for use in the genetically modified cells and methods described herein include, but are not limited to, Red Star Montrachet, EC-1118, Elegance, Red Star Côte des Blancs, Epernay II, Red Star Premier Cuvée, Red Star Pasteur Red, Red Star Pasteur Champagne, Fermentis BCS-103, and Fermentis VR44. In some embodiments, the yeast is S. cerevisiae strain Elegance. In some embodiments, the yeast is S. cerevisiae strain EC-1118 (also referred to as EC1118 or Lalvin EC 1118® (Lallemand Brewing)).
[0167] In some embodiments, the modified cells are S. cerevisiae cells that express FAS2 under the control of the PRB1 promoter and MpAAT1-A169G,A170F under the control of the PGK1 promoter. In some embodiments, the modified cells also contain deletions of EHT1 and EEB1.
[0168] In some embodiments, the modified cell is an S. cerevisiae cell that expresses FAS2 under the control of the PRB1 promoter and MpAAT1-A169G,A170F under the control of the PGK1 promoter.
[0169] In some embodiments, the modified cells are S. cerevisiae expressing FAS2-G1250S under the control of the PRB1 promoter and MpAAT1-A169G,A170F under the control of the PGK1 promoter. In some embodiments, the modified cells also contain a deletion of EHT1.
[0170] In some embodiments, the modified cell is an S. cerevisiae cell expressing FAS2-G1250S under the control of the PRB1 promoter and MpAAT1-A169G,A170F under the control of the PGK1 promoter. In some embodiments, the modified cell also contains deletions of EHT1 and EEB1.
[0171] In some embodiments, the modified cells are S. cerevisiae cells that express FAS2-G1250S under the control of the PRB1 promoter and MpAAT1-A169G,A170F under the control of the PGK1 promoter. In some embodiments, the modified cells also contain deletions of EHT1, EEB1, and MGL2.
[0172] In some embodiments, the modified cells are S. cerevisiae cells that express FAS2-G1250S under the control of the PRB1 promoter, MpAAT1-A169G,A170F under the control of the PGK1 promoter, and HCS under the control of the PDC6 promoter. In some embodiments, the modified cells also contain deletions of EHT1, EEB1, and MGL2.
[0173] In some embodiments, the modified cell is an S. cerevisiae cell that expresses FAS2-G1250S under the control of the PRB1 promoter and MaWES1 under the control of the QCR10 promoter. In some embodiments, the modified cell is an S. cerevisiae cell that expresses FAS2-G1250S under the control of the PRB1 promoter and MaWES1 under the control of the HEM13 promoter. In some embodiments, the modified cell also contains a deletion of EHT1 and EEB1.
[0174] method Aspects of the present disclosure relate to methods of producing fermentation products using any of the genetically modified yeast cells described herein. Also provided are methods of producing ethanol using any of the genetically modified yeast cells described herein.
[0175] The process of fermentation utilizes natural processes that use microorganisms to convert carbohydrates into alcohol and carbon dioxide. It is a metabolic process that produces chemical changes in organic substrates through enzymatic action. In the context of food production, fermentation broadly refers to any process in which microbial activity brings about a desired change in a food or beverage. The conditions and execution of fermentation are referred to herein as the "fermentation process."
[0176] In some aspects, the present disclosure relates to methods for producing a fermentation product, such as a fermented beverage, that involve contacting any of the modified cells described herein with a medium containing at least one fermentable sugar during an initial fermentation process to produce the fermentation product. "Medium," as used herein, refers to a liquid that is conducive to fermentation and does not inhibit or prevent the fermentation process. In some embodiments, the medium is water. In some embodiments, the method for producing a fermentation product involves contacting purified enzymes (e.g., any of the alcohol-O-acyltransferase, fatty acid synthase, and / or hexanoyl-CoA synthetase enzymes described herein) with a medium containing at least one fermentable sugar during the initial fermentation process to produce the fermentation product.
[0177] As also used herein, the term "fermentable sugar" refers to a carbohydrate that can be converted by a microorganism, such as any of the cells described herein, to alcohol and carbon dioxide. In some embodiments, the fermentable sugar is converted by an enzyme, such as a recombinant enzyme, or a cell expressing the enzyme, to alcohol and carbon dioxide. Examples of fermentable sugars include, but are not limited to, glucose, fructose, lactose, sucrose, maltose, and maltotriose.
[0178] In some embodiments, the fermentable sugars are provided in a sugar source. The sugar source for use in the claimed methods can depend, for example, on the type of fermentation product and fermentable sugar. Examples of sugar sources include, but are not limited to, malt, grains / cereals, fruit juice (e.g., grape juice and apple juice / apple wine), honey, cane sugar, rice, and koji. Examples of fruits from which juice can be obtained include, but are not limited to, grapes, apples, blueberries, blackberries, raspberries, currants, strawberries, cherries, pears, peaches, nectarines, oranges, pineapples, mangoes, and passion fruit.
[0179] As will be apparent to those skilled in the art, in some cases, it may be necessary to process the sugar source to make fermentable sugars available for fermentation. Using the production of beer as an example of a fermented beverage, grains (cereals, barley) are boiled or steeped in water, which hydrates the grain and activates malt enzymes, converting starch to fermentable sugars, a process known as "mashing." As used herein, the term "wort" refers to the liquid produced in the saccharification process and containing fermentable sugars. The wort is then exposed to a fermenting organism (e.g., any of the cells described herein), allowing the enzymes of the fermenting organism to convert the sugars in the wort to alcohol and carbon dioxide. In some embodiments, the wort is contacted with a recombinant enzyme (e.g., any of the enzymes described herein), which may optionally be purified or isolated from the organism that produces the enzyme, allowing the enzyme to convert the sugars in the wort to alcohol and carbon dioxide.
[0180] In some embodiments, the grains are malted, unmalted, or comprise a combination of malted and unmalted grains. Examples of grains for use in the methods described herein include, but are not limited to, barley, oats, corn, rice, rye, sorghum, wheat, oats, and pearl barley.
[0181] In the example of producing sake, the sugar source is rice, and the rice is incubated with Aspergillus oryzae to convert the rice starch into fermentable sugars, producing koji. The koji is then exposed to a fermenting organism (e.g., any of the cells described herein), allowing enzymes in the fermenting organism to convert the sugars in the koji to alcohol and carbon dioxide. In some embodiments, the koji is contacted with a recombinant enzyme (e.g., any of the enzymes described herein), optionally purified or isolated from the organism that produces the enzyme, allowing the enzyme to convert the sugars in the koji to alcohol and carbon dioxide.
[0182] In the example of producing wine, grapes are harvested and mashed (e.g., crushed) into a composition containing skins, pulp, juice, and seeds. The resulting composition is referred to as "must." The grape juice may be separated from the must and fermented, or the entire must (i.e., skins, seeds, and pulp) may be fermented. The grape juice or must is then exposed to a fermenting organism (e.g., any of the cells described herein), allowing enzymes in the fermenting organism to convert sugars in the grape juice or must into alcohol and carbon dioxide. In some embodiments, the grape juice or must is contacted with a recombinant enzyme (e.g., any of the enzymes described herein), optionally purified or isolated from the organism that produces the enzyme, allowing the enzyme to convert sugars in the grape juice or must into alcohol and carbon dioxide.
[0183] In some embodiments, the methods described herein involve producing a medium, which may involve heating or soaking a sugar source, for example, in water. In some embodiments, the water has a temperature of at least 50 degrees Celsius (50°C) and is incubated with the sugar source for a period of time. In some embodiments, the water has a temperature of at least 75°C and is incubated with the sugar source for a period of time. In some embodiments, the water has a temperature of at least 100°C and is incubated with the sugar source for a period of time. Preferably, the medium is cooled prior to the addition of any of the cells described herein.
[0184] In some embodiments, the methods described herein further include adding at least one hop variety (e.g., one, two, three, four, five, or more) to the wort, e.g., to the medium, during the fermentation process. Hops are the flowers of the hop plant (Humulus lupulus) and are often used in fermentation to impart various flavors and aromas to the fermentation product. Hops are considered to impart bitter flavoring in addition to floral, fruity, and / or citrus flavors and aromas, and may be characterized based on their intended purpose. For example, bittering hops impart a certain level of bitterness to the fermentation product due to the presence of alpha acids in the hop flowers, while aromatic hops have lower levels of alpha acids and contribute desirable aromas and flavors to the fermentation product.
[0185] Whether one or more varieties of hops are added to the medium and / or wort, and at what stage the hops are added, may depend on various factors, such as the intended purpose of the hops. For example, hops intended to impart bitterness to the fermentation product are typically added during wort preparation, e.g., during the boiling of the wort. In some embodiments, hops intended to impart bitterness to the fermentation product are added to the wort and boiled with the wort for a period of time, e.g., about 15 to 60 minutes. In contrast, hops intended to impart a desired aroma to the fermentation product are typically added after the hops used for bittering. In some embodiments, hops intended to impart a desired aroma to the fermentation product are added at the end of the boil or after the wort has been boiled (i.e., "dry hopping"). In some embodiments, one or more varieties of hops may be added multiple times during the process (e.g., at least two times, at least three times, or more times).
[0186] In some embodiments, hops are added in the form of either wet hops or dried hops, and may optionally be boiled with the wort. In some embodiments, hops are in the form of dried hop pellets. In some embodiments, at least one variety of hops is added to the medium. In some embodiments, hops are wet (i.e., not dried). In some embodiments, hops are dry and may optionally be further processed prior to use. In some embodiments, hops are added to the wort prior to the fermentation process. In some embodiments, hops are boiled in the wort. In some embodiments, hops are boiled with the wort and then cooled with the wort.
[0187] Many varieties of hops are known in the art and may be used in the methods described herein. Examples of hop varieties include, but are not limited to, Ahtanum, Amarillo, Apollo, Cascade, Centennial, Chinook, Citra, Cluster, Columbus, Crystal / Chrystal, Eroica, Galena, Glacier, Greenburg, Horizon, Liberty, Millennium, Mosaic, Mount Hood, Mount Rainier, Newport, Nugget, Palisade, Santiam, Simcoe, Sterling, Summit, Tomahawk, Ultra, Vanguard, Warrior, Willamette, Zeus, Admiral, Brewer's Gold, Bullion, Challenger, First Gold, Fuggles, Goldings, Herald, Northdown, Northern Brewer, Phoenix, Pilot, Pioneer, Progress, Target, and Whitbread Golding. Variety(WGV), Hallertau, Hersbrucker, Saaz, Tettnang, Spalt, Feux-Coeur Francais, Galaxy, Green Bullet, Motueka, Nelson Sauvin, Pacific Gem, Pacific Jade, Pacifica, Pride of Ringwood, Riwaka, Southern Cross, Lublin, Magnum, Perle, Polnischer Lublin, Saphir, Satus, Select, Strisselspalt, Styrian Goldings, Tardif de Bourgogne, Tradition, Bravo, Calypso, Chelan, Comet, El Dorado, San Juan Ruby Red, Satus, Sonnet Golding, Super Galena, Tillicum, Bramling Cross, Pilgrim, Hallertauer Herkules, Hallertauer Magnum, HallertauerTaurus, Merkur, Opal, Smaragd, Halleratau Aroma, Kohatu, Rakau, Stella, Sticklebract, Summer Saaz, Super Alpha, Super Pride, Topaz, Wai-iti, Bor, Junga, Marynka, Premium, Sladek, Styrian Atlas, Styrian Aurora, Styrian Bobek, Styrian Celeia, Sybilla Sorachi Includes Ace, Hallertauer Mittelfrueh, Hallertauer Tradition, Tettnanger, Tahoma, Triple Pearl, Yahima Gold, and Michigan Copper.
[0188] In some embodiments, the fermentation process of at least one sugar source comprising at least one fermentable sugar may be carried out for about 1 day to about 31 days. In some embodiments, the fermentation process is carried out for about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, or longer. In some embodiments, the fermentation process of one or more fermentable sugars may be carried out at a temperature of about 4°C to about 30°C. In some embodiments, the fermentation process of one or more fermentable sugars may be carried out at a temperature of about 8°C to about 14°C or about 18°C to about 24°C. In some embodiments, the fermentation process of one or more fermentable sugars may be carried out at a temperature of about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, or 30°C.
[0189] In some embodiments, the fermentation results in a reduction in the amount of fermentable sugars present in the medium, hi some embodiments, the reduction in the amount of fermentable sugars occurs within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, or more from the start of the fermentation. In some embodiments, the amount of fermentable sugars is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%, or 100%. In some embodiments, the modified cell(s) ferment a similar or greater amount of fermentable sugars compared to the amount of fermentable sugars fermented by a wild-type yeast cell in the same amount of time.
[0190] The methods described herein may involve at least one additional fermentation process. Such an additional fermentation process may be referred to as a secondary fermentation process (also referred to as "aging" or "maturing"). As will be understood by those skilled in the art, secondary fermentation typically involves transferring the fermented beverage to a second container (e.g., a glass carboy, a barrel) where the fermented beverage is incubated for a period of time. In some embodiments, the secondary fermentation is carried out for a period of time between 10 minutes and 12 months. In some embodiments, the secondary fermentation is carried out for a period of time ranging from 10 minutes, 20 minutes, 40 minutes, 40 minutes, 50 minutes, 60 minutes (1 hour), 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days ... The fermentation process may be carried out for a period of time ranging from about 4° C. to about 30° C., such as from about 8° C. to about 14° C., or from about 18° C. to about 24° C. In some embodiments, the ... In some embodiments, the fermentation process may be carried out for a period of time ranging from about 4° C. to about 30° C. In some embodiments, the fermentation process may be carried out for a period of time In some embodiments, the additional or secondary fermentation process of one or more fermentable sugars may be carried out at a temperature of about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, or 30°C.
[0191] As will be apparent to one skilled in the art, the selection of the duration and temperature for the additional or secondary fermentation process will depend on factors such as the type of beer, the desired beer characteristics, and the yeast strain used in the process.
[0192] In some embodiments, one or more additional flavor components may be added to the medium prior to or after the fermentation process. Examples include hop oil, hop aromatics, hop extract, hop bitterness, and isomerized hop extract.
[0193] Products from the fermentation process may volatilize and dissipate during the fermentation process or from the fermentation product. For example, ethyl hexanoate produced during fermentation using the cells described herein may volatilize, resulting in reduced levels of ethyl hexanoate in the fermentation product. In some embodiments, the volatilized ethyl hexanoate is captured and reintroduced after the fermentation process.
[0194] Following fermentation, there may be various refinement, filtering, and aging processes before the liquid is bottled (e.g., retained and sealed in a container for distribution, storage, or consumption). Any of the methods described herein may further involve distilling, pasteurizing, and / or carbonating the fermented product. In some embodiments, the method involves carbonating the fermented product. Methods of carbonating fermented beverages are known in the art and include, for example, forced carbonation with a gas (e.g., carbon dioxide, nitrogen), natural carbonation by adding an additional sugar source to the fermented beverage to promote further fermentation and carbon dioxide production (e.g., bottle conditioning).
[0195] fermentation products Aspects of the present disclosure relate to a fermentation product produced by any of the methods disclosed herein. In some embodiments, the fermentation product is a fermented beverage. Examples of fermented beverages include, but are not limited to, beer, wine, sake, mead, apple cider, cava, sparkling wine (champagne), kombucha, ginger beer, and water kefir. In some embodiments, the beverage is beer. In some embodiments, the beverage is wine. In some embodiments, the beverage is sparkling wine. In some embodiments, the beverage is champagne. In some embodiments, the beverage is sake. In some embodiments, the beverage is mead. In some embodiments, the beverage is apple cider. In some embodiments, the beverage is hard seltzer. In some embodiments, the beverage is a wine cooler.
[0196] In some embodiments, the fermentation product is a fermented food. Examples of fermented foods include, but are not limited to, cultured yogurt, tempeh, miso, kimchi, sauerkraut, fermented sausage, bread, and soy sauce.
[0197] According to aspects of the present invention, increased titers of ethyl hexanoate are produced through recombinant expression of genes associated with the present invention in yeast cells and use of said cells in the methods described herein. As used herein, "increased titer" or "high titer" refers to titer on the nanograms per liter (ng L) scale. The titer produced for a given product will be influenced by multiple factors, including the selection of the medium and conditions for fermentation.
[0198] In some embodiments, the titer of ethyl hexanoate is at least 1 μg L -1, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 50 0, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1050, 1100, 1200, 1300, 1400, 150 0, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000μg L -1 is.
[0199] Aspects of the present disclosure relate to reducing the production of undesired products (e.g., by-products, off-flavors), such as hexanoic acid, during fermentation of a product. In some embodiments, expression of an alcohol-O-acyltransferase, a fatty acid synthase, and / or a hexanoyl-CoA synthetase in a genetically modified cell described herein results in a reduction in the production of an undesired product (e.g., hexanoic acid) by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to the production of an undesired product (e.g., hexanoic acid) by using a wild-type yeast cell or a yeast cell that does not express the enzyme.
[0200] In some embodiments, the potency of hexanoic acid is 1000 mg L -1 Less than, for example, 1000, 950, 900, 850, 800, 750, 700, 650, 600, 550, 500, 450, 400, 350, 300, 250, 200, 150, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 mg L -1 Less than or less than.
[0201] Methods for measuring the potency / level of ethyl hexanoate and / or hexanoic acid will be apparent to those skilled in the art. In some embodiments, the potency / level of volatile thiol and / or indole is measured using gas chromatography-mass spectrometry (GC / MS). In some embodiments, the potency / level of ethyl hexanoate and / or hexanoic acid is assessed using a sensory panel, including, for example, human taste testers.
[0202] In some embodiments, the fermented beverage contains between 0.1% and 30% alcohol by volume (also referred to as "ABV," "abv," or "alc / vol"). In some embodiments, the fermented beverage contains about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.07%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% or more alcohol by volume. In some embodiments, the fermented beverage is non-alcoholic (eg, having less than 0.5% alcohol by volume).
[0203] kit Aspects of the present disclosure also provide kits for use of genetically modified yeast cells, e.g., to produce fermented beverages, fermentation products, or ethanol. In some embodiments, the kits contain modified cells containing a heterologous gene encoding an enzyme with alcohol-O-acyltransferase (AAT) activity, an exogenous gene encoding an enzyme with fatty acid synthase (FAS2) activity, and / or a heterologous gene encoding an enzyme with hexanoyl-CoA (HCS) activity.
[0204] In some embodiments, the kit is for the production of a fermented beverage. In some embodiments, the kit is for the production of beer. In some embodiments, the kit is for the production of wine. In some embodiments, the kit is for the production of sake. In some embodiments, the kit is for the production of mead. In some embodiments, the kit is for the production of apple wine.
[0205] The kits may also include other components for use in any of the methods described herein or for use of any of the cells as described herein. For example, in some embodiments, the kits may contain grain, water, wort, must, yeast, hops, fruit juice, or other sugar source(s). In some embodiments, the kits may contain one or more fermentable sugars. In some embodiments, the kits may contain one or more additional agents, ingredients, or components.
[0206] Instructions for practicing the methods described herein may also be included in the kits described herein.
[0207] The kits may be arranged to indicate a single-use composition containing any of the modified cells described herein. For example, the single-use composition (e.g., the amount to be used) may be a packaged composition (e.g., modified cells), such as a packeted (i.e., contained in a packet) powder, vial, ampoule, culture tube, tablet, caplet, capsule, or liquid-containing sachets.
[0208] The composition (e.g., the modified cells) may be provided in a dried, lyophilized, frozen, or liquid form. In some embodiments, the modified cells are provided as colonies on an agar medium. In some embodiments, the modified cells are provided in the form of a seed culture that may be directly added to a medium. When a reagent or component is provided in a dried form, it is generally reconstituted by the addition of a solvent, such as a medium. The solvent may be provided in another packaging means and may be selected by one of skill in the art.
[0209] Numerous packages or kits for dispensing compositions (e.g., modified cells) are known to those of skill in the art. In some embodiments, the package is a labeled blister package, a dial dispenser package, a tube, a packet, a drum, or a bottle.
[0210] Any of the kits described herein may further include one or more vessels for carrying out the methods described herein, such as a carboy or barrel.
[0211] general technique The practice of the subject matter of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques include, but are not limited to, Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012; Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (JECellis, ed., 1998) Academic Press; Animal Cell Culture (RIFreshney, ed., 1987); Introduction to Cell and Tissue Culture (JP Mather and PE Roberts, 1998) Plenum Press; Sons;Methods in Enzymology(Academic Press, Inc.);Handbook of Experimental Immunology (DMWeir and CCBlackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JMMiller and MPCalos, eds., 1987); Current Protocols in Molecular Biology (FMAusubel, et al., eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis, et al., eds., 1994); Current Protocols in Immunology (JE Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999).
[0212] Equivalence and Scope It is to be understood that the present disclosure is not limited to any or all of the particular embodiments expressly described herein, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0213] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Also, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, the preferred methods and materials are described herein.
[0214] All publications and patents cited in this disclosure are cited to disclose and describe methods and / or materials related to the methods and / or materials for which the publications are cited. All such publications and patents are incorporated by reference herein as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and / or materials described in the cited publications and patents and does not extend to any lexical definitions from the cited publications and patents (i.e., any lexical definitions from cited publications and patents that are not expressly repeated in this disclosure should not be treated as such and should not be read as defining any terms that appear in the appended claims). In the event of a conflict between any of the incorporated references and this disclosure, the present disclosure shall control. Additionally, any specific aspects of the present disclosure that are within the prior art may be expressly excluded from any one or more of the claims. Such aspects may be excluded, even if the exclusion is not expressly expressed in the specification, as being known to those of ordinary skill in the art. Any specific aspect of the present disclosure may be excluded from any claim for any reason, whether or not related to the existence of prior art.
[0215] The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0216] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features that may be readily separated from or combined with any of the features of the other several embodiments without departing from the spirit or scope of the disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically feasible.
[0217] Articles such as "a," "an," and "the" in the claims may mean one or more than one, unless indicated to the contrary or otherwise clear from the context. Whenever pronouns are used herein in a gender (e.g., masculine, feminine, neuter, etc.), the pronouns shall be construed as gender-neutral (i.e., interpreted as referring equally to all genders) regardless of implied gender, unless the context clearly indicates or requires otherwise. Whenever used herein, words used in the singular include the plural, and words used in the plural include the singular, unless the context clearly indicates or requires otherwise. A claim or description including "or" between one or more members of a group is deemed to be satisfied when one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process, unless indicated to the contrary or otherwise clear from the context. The present disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The present disclosure includes embodiments in which more than one, or all, of the group members are present in, employed in, or otherwise relevant to a given product or process.
[0218] Furthermore, the present disclosure covers all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the enumerated claims are introduced into another claim. For example, any claim that depends on another claim can be modified to include one or more limitations found in any other claim that depends on the same base claim. Where elements are presented as lists (e.g., in Markush group format), each subgroup of elements is also disclosed, and any element(s) can be removed from the group. In general, when the present disclosure or aspects of the disclosure are referred to as comprising specific elements and / or features, it should be understood that certain embodiments of the disclosure or aspects of the disclosure consist of, or consist essentially of, such elements and / or features. For purposes of simplicity, those embodiments have not been so specifically described herein. Note also that the terms "comprising" and "containing" are intended to be open, allowing for the inclusion of additional elements or steps. Where ranges are given, endpoints are included in such ranges unless otherwise specified. Furthermore, unless otherwise indicated or apparent from the context and the understanding of one of ordinary skill in the art, values expressed as ranges may assume that any particular value or subrange within the stated range in various aspects of the present disclosure is to one-tenth of the unit of the lower limit of the range unless the context clearly dictates otherwise.
[0219] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. The scope of the embodiments described herein is not intended to be limited to the above description, but rather is as set forth in the appended claims. Those skilled in the art will appreciate that various changes and modifications to this description may be made, as defined in the following claims, without departing from the spirit or scope of the present disclosure.
[0220] example Example 1 Identification of AAT for improved ethyl hexanoate biosynthesis To develop genetically modified cells that produce increased levels of ethyl hexanoate during beer and wine fermentation, we balanced ethyl hexanoate production with maintaining hexanoic acid concentrations below the flavor detection threshold and the resulting growth / replication of the genetically modified cells. First, we identified candidate alcohol-O-acyltransferases (AATs) capable of producing ethyl hexanoate but with minimal ester hydrolase and acyl-CoA thioesterase activity. Given the large and functionally diverse AAT enzyme family, we hypothesized that non-endogenous yeast AATs might exhibit superior activity in this regard compared to endogenous yeast enzymes. A literature search identified a set of 11 candidate enzymes from fungal, bacterial, and plant sources that have previously been shown to have or are likely to have ethyl hexanoate biosynthetic activity. Genes encoding candidate AAT enzymes under the transcriptional control of the strong glycolytic promoter pPGK1 were synthesized and transformed into the California Ale brewing yeast strain. The transformed strains were grown semi-anaerobic in brewer's wort medium to mimic beer fermentation. After 5 days of fermentation, samples from each culture were run by GC-MS to measure the concentrations of ethyl hexanoate and hexanoic acid in the medium. Data from this experiment revealed that expression of the variant AAT from Marinobacter aquaeolei (hereinafter referred to as "MaWES") resulted in the highest concentration of ethyl hexanoate and the highest ratio of ethyl hexanoate to hexanoic acid. Ethyl hexanoate and hexanoic acid levels in fermentations with strains expressing MaWES were 5-fold and 2-fold higher, respectively, than in fermentations using strains overexpressing the endogenous yeast AAT, EEB1.
[0221] The MaWES AAT enzyme has previously been evaluated to utilize its activity in biofuel production. Two single amino acid mutations were found to alter the enzyme's substrate specificity. For example, Barney et al. found that the A360I mutation increased the relative binding affinity of MaWES for C8–C10 alcohol substrates while decreasing its affinity for C12–14 alcohol substrates. See Barney et al. Appl. Environ. Microbiol. (2013) 79:5734–5745. Additionally, Petronikolou and Nair found that the A144F mutation increased the binding affinity for hexanoyl-CoA while decreasing its affinity for longer-chain acyl-CoA substrates. See Petronikolou et al. ACS Catal. (2018) 8:6334–6344. However, the production of ethyl hexanoate or ester flavor molecules by either the wild-type or mutant MaWES enzymes was not evaluated.
[0222] Substitution mutations were introduced at positions A360 and A144 in MaWES (A360I and A144F), and the resulting strains were evaluated for ethyl hexanoate biosynthesis in comparison with the wild-type enzyme. The MaWES mutant enzyme (MaWES) was expressed under the control of the constitutive 3-phosphoglycerate kinase promoter pPGK1. A360I,A144F A Cal Ale yeast strain expressing the BY719 gene was generated. This strain was designated BY719 and was used to brew beer in a 5-gallon fermentation.
[0223] Beer brewed with BY719 was analyzed by a sensory tasting panel, and the concentrations of ethyl hexanoate and hexanoic acid were quantified by gas chromatography / mass spectrometry (GC / MS). The tasting panel's notes indicated that the beer contained a very light pineapple flavor, but that a sweet off-flavor characteristic of goat was also present. Consistent with these tasting notes, GC / MS analysis revealed that the concentration of ethyl hexanoate in the beer was two-fold higher than in beer brewed with a control, unmodified (wild-type) strain, but that hexanoic acid levels were also four-fold higher than in the control beer. Additionally, in contrast to the control strain, the MaWES mutant enzyme (MaWES A360I,A144F ) did not fully metabolize all of the fermentable sugars present in the brewed wort. Such "incomplete fermentation" generally results from strain engineering efforts that produce off-target effects that negatively affect cellular energetics or increase the production of growth-inhibitory metabolic by-products. Incomplete fermentation often results in sweet, high-calorie beers that are generally not commercially viable.
[0224] Based on these experimental fermentations, the MaWES mutant enzyme (MaWES A360I,A144F It was concluded that strong expression of the MaWES mutant enzyme (MaWES) resulted in more ethyl hexanoate and a higher ratio of ethyl hexanoate to hexanoic acid than the S. cerevisiae WLP001 strain similarly engineered to overexpress EEB1. Second, the concentration of ethyl hexanoate in beer brewed by BY719 may be too low to have a significant effect on beer flavor, and the concentration of hexanoic acid that imparts the undesirable goat-specific off-flavor was high enough above the human detection threshold. Third, the MaWES mutant enzyme (MaWES) A360I,A144F Expression of the MaWES mutant enzyme (MaWES) resulted in a growth defect in the strain that prevented BY719 from fully consuming the fermentable sugars present in beer fermentation. A360I,A144FIt was demonstrated that yeast expressing ) showed potential for improving pineapple flavor in fermented beverages, but further development is required to 1) further increase ethyl hexanoate production, 2) reduce hexanoic acid production, and 3) eliminate the growth defects of the strain.
[0225] Improving ethyl hexanoate production by combining MaWES expression with increased hexanoyl-CoA biosynthesis The BY719 strain was further modified to increase the concentration of ethyl hexanoate produced during fermentation. Because hexanoyl-CoA is a substrate in the reaction that produces ethyl hexanoate and thus may be the limiting compound, the yeast strain was modified to express fatty acid synthase subunit alpha (FAS2) containing the G1250S mutation to increase hexanoyl-CoA production. To this end, the G1250S mutation was introduced at the endogenous FAS2 locus in the yeast genome. The FAS2 G1250S strain was engineered to express the MaWES mutant enzyme (MaWES) driven by the delta-9 fatty acid desaturase promoter pOLE1 (a medium-strength promoter). A360I,A144F ), resulting in a strain designated BY580.
[0226] BY580 was grown in small-scale brewing fermentations, after which the production of ethyl hexanoate and hexanoic acid, as well as sugar consumption, was measured. This strain produced more ethyl hexanoate and more hexanoic acid compared to BY719. However, like BY719, strain BY580 also grew poorly and did not completely consume the fermentable sugars present in the brewing wort medium. These results suggest that the FAS2 G1250S mutation is a key regulator of the MaWES mutant enzyme (MaWES). A360I,A144F ), we were able to successfully increase ethyl hexanoate production, but demonstrated that additional developments were also required to reduce the co-production of hexanoic acid and alleviate the growth defect of the strain.
[0227] Altering the expression of MaWES and FAS2 G1250S genes to improve growth and ethyl hexanoate production We hypothesized that the growth defect observed in strain BY580 could be due to a reduction in essential C16 and C18 fatty acids resulting from the FAS2 G1250S mutation, which, combined with the anaerobic and high-ethanol brewing environment, could inhibit yeast growth. Alternatively or additionally, we hypothesized that the increased C6-C10 fatty acids produced by the strain inhibit growth by disrupting the transmembrane proton gradient, as previously reported (see, e.g., Viegas et al. Appl. Environ. Microbiol. (1989). 55:21-28). FAS2 G1250S and the MaWES mutant enzyme (MaWES) A360I,A144F ) expression levels were varied to determine the effect on the levels of ethyl-hexanol and hexanoic acid produced during fermentation, while also potentially assessing whether it alleviates the metabolic defect.
[0228] More than 30 strains were constructed, each of which contained a mutant MaWES enzyme (MaWES A360I,A144F ) and FAS2-G1250S. These strains express wild-type FAS2 under the control of the wild-type native FAS2 promoter and the MaWES mutant enzyme (MaWES) under the control of the first yeast-derived promoter. A360I,A144F The native FAS2 locus of each strain was unmodified to express FAS2-G1250S under the control of a second yeast-derived promoter, and FAS2-G1250S under the control of a second yeast-derived promoter. Each of these strains was grown in small-scale brewery wort fermentations, after which the levels of ethyl hexanoate and hexanoic acid were determined. A360I,A144FThe promoters driving the expression of the FAS2-G1250S and FAS2-G1250S genes were found to have significant effects on the concentrations of ethyl hexanoate and hexanoic acid produced, strain growth, and sugar consumption by the strains. One strain, BY845, was found to produce over three times more ethyl hexanoate and nine times more hexanoic acid than the unmodified wild-type control strain while growing identically to the control. Compared to strain BY580, BY845 exhibited improved growth and produced slightly less ethyl hexanoate and much less hexanoic acid.
[0229] BY845 was used in a 5-gallon beer fermentation to assess strain growth and ethyl hexanoate / hexanoic acid production in a scaled-up brewing environment. Throughout the 10-day fermentation, the sugar consumption profile of BY845 was identical to that of the control strain. The beer produced by BY845 was characterized as having a strong, distinctive pineapple-tasting note and slight off-flavor notes described as "goat-specific." GC / MS analysis of the beer revealed that the concentrations of ethyl hexanoate and hexanoic acid were 5.7- and 6.8-fold higher in this beer than in the control strain. The MaWES mutant enzyme (MaWES A360I,A144F The specific combination of promoter sequences driving expression of the BY845 and FAS2 G1250S genes was sufficient to alter the levels and ratios of ethyl hexanoate and hexanoic acid produced during fermentation and alleviate the growth defects observed in BY719 and BY580. Additionally, although the concentration of ethyl hexanoate produced by BY845 was only 5.7-fold higher than that of the control strain, it was sufficient to impart a strong pineapple flavor to the beer. Finally, the concentration of hexanoic acid produced by BY845 was similar to that produced by the previous strains, and the beer produced by BY845 was perceived as having a characteristic goat off-flavor during beer sensory analysis. These results indicated that further development to reduce hexanoic acid production is still needed.
[0230] Expression of hexanoyl-CoA synthetase and depletion of endogenous AAT reduces hexanoic acid production To reduce the amount of hexanoic acid produced during fermentation, two complementary approaches were evaluated: expression of hexanoyl-CoA synthetase and deletion of the endogenous yeast AAT enzyme.
[0231] As described herein, the hexanoyl-CoA synthetase (HCS) enzyme catalyzes the formation of hexanoyl-CoA from the substrates hexanoic acid and free CoA. Given that this reaction produces hexanoyl-CoA, a precursor for ethyl hexanoate biosynthesis, while also destroying hexanoic acid, expression of HCS can reduce the levels of hexanoic acid produced by strains such as BY845. Toward this end, a MaWES mutant enzyme (MaWES A360I,A144F Strains expressing FAS2-G1250S and FAS2-G1250S were further modified to express the HCS enzyme (HCS23) from Cannabis sativa driven by the methyl sterol monooxygenase promoter (pERG25), considered a moderate-strength promoter. These strains were assessed by small-scale wort fermentation followed by GC / MS analysis, which revealed that HCS expression reduced the levels of hexanoic acid in the fermentation medium but also led to strain growth defects and incomplete fermentation.
[0232] To identify an HCS expression regime that does not impair cell growth, additional strains were also engineered to express HCS under the control of several different yeast-derived promoters. The results of these experiments indicated that strain BY888, expressing MaWES, FAS2-G1250S, and HCS under the pHEM13 promoter (which induces strong expression during the later stages of fermentation), grew comparable to the unmodified control strain and produced less hexanoic acid than BY845.
[0233] FAS2-G1250S and MaWES mutant enzyme (MaWES A360I,A144FA second approach was explored to reduce hexanoic acid production in strains expressing the endogenous yeast AAT enzyme (i.e., deletion of the endogenous yeast AAT enzyme). The endogenous yeast AAT enzyme is thought to produce hexanoic acid through the hydrolysis of ethyl hexanoate and hexanoyl-CoA. The yeast genome is predicted to encode at least seven AAT enzymes, which are thought to have abundant ester and acyl-CoA hydrolysis activity. A single deletion of the endogenous AAT enzyme EEB1 reduced hexanoic acid production in strains expressing the FAS2 G1250S and MaWES mutant enzymes (MaWES A360I,A144F It was found that deletion of AAT resulted in a modest but significant reduction in hexanoic acid levels in strains expressing AAT. Interestingly, deletion of several other AATs resulted in growth defects with respect to sugar consumption during fermentation.
[0234] Example 2 Generation of genetically modified strains capable of producing increased levels of ethyl hexanoate and reduced levels of hexanoic acid To generate a genetically modified strain for beer brewing that produces increased levels of ethyl hexanoate and decreased levels of hexanoic acid, the wild-type Saccharomyces cerevisiae strain WLP001 (CA01) was transformed with the constructs shown in Table 1. The transformed strain was grown semi-anaerobic in malt extract fermentation for 5 days, after which the concentrations of ethyl hexanoate and hexanoic acid were then measured by GC-MS (Figures 1A and 1B).
[0235] As shown in Figure 1A, overexpression of FAS2-G1250S and MpAAT1_AA169GF resulted in an 11.9-fold increase in ethyl hexanoate production and a 10.4-fold increase in the production of the off-flavor molecule hexanoic acid (strain y1059, compared to CA01). Deletion of the endogenous AAT, EHT1, in strain y1059 reduced hexanoic acid production by over half while maintaining high levels of ethyl hexanoate production (strain y1227, compared to strain y1059). Deletion of a second endogenous AAT, EEB1, in strain y1227 further reduced hexanoic acid production and modestly reduced ethyl hexanoate production compared to strains in which one endogenous AAT was deleted (strain y1076, compared to strain y1227). In addition, deletion of a third endogenous AAT, MGL2, in strain y1170 resulted in modestly reduced hexanoic acid production compared to strains in which two endogenous AATs were deleted, but did not affect ethyl hexanoate production (strain y1170 compared to strain y1076).
[0236] Expression of hexanoyl-CoA synthetase (HCS) in strain y1170 further reduced hexanoic acid production without significantly affecting ethyl hexanoate production compared to the corresponding strain not expressing HCS (compare strain y1210 with strain y1170). Strain y1210 was found to produce 14.44 mg / L ethyl hexanoate (an 8.49-fold increase compared to the level of ethyl hexanoate produced by wild-type CA01) and 1.5 mg / L hexanoic acid (a 1.15-fold increase compared to the level of hexanoic acid produced by wild-type CA01) (Figure 1B). Overexpression of the wild-type FAS2 gene and MpAAT1_AA169GF in a strain lacking the endogenous AATs EEB1 and EHT1 resulted in a 2.7-fold increase in ethyl hexanoate production and an approximately 2-fold reduction in hexanoic acid production.
[0237] To generate genetically modified yeast strains for producing wine with increased levels of ethyl hexanoate and decreased levels of hexanoic acid, S. cerevisiae strains EC1118 and Elegance were transformed with the constructs shown in Table 1. The strain was grown in grape juice medium for 14 days, after which the concentrations of ethyl hexanoate and hexanoic acid in the fermentation medium were determined by GC-MS (Figures 2A and 2B).
[0238] As shown in Figures 2A and 2B, genetically modified strains expressing FAS2-G1250S and a heterologous AAT (either MaWES or MpAAT1) were able to produce increased levels of ethyl hexanoate compared to wild-type S. cerevisiae strain EC1118 (strains y786, y796, and y1134, compared to wild-type strain EC1118). With the exception of y1134, the tested strains also produced increased levels of the off-flavor molecule hexanoic acid. However, for some strains, deletion of the endogenous AATs EEB1 and EHT1 was found to improve the ethyl hexanoate to hexanoic acid production ratio compared to the ratio in strains containing endogenous AAT (strain y1134, compared to strain y1138) (see Figure 2B).
[0239] Table 1. Yeast strains assayed in Example 2 [Table 1]
Claims
1. (i) a first gene operably linked to a first promoter, where the first gene is a heterologous gene encoding an enzyme having alcohol-O-acyltransferase (AAT) activity; and (ii) one or more additional genes selected from the group consisting of: (a) a gene encoding an enzyme having fatty acid synthase (FAS2) activity, operably linked to a promoter; and (b) a gene encoding an enzyme having hexanoyl-CoA-synthetase (HCS) activity, operably linked to a promoter; A genetically modified yeast cell comprising:
2. 2. The genetically modified yeast cell of claim 1, wherein the enzyme having AAT activity is derived from Marinobacter hydrocarbonoclasticus, Fragraia x ananassa, Saccharomyces cerevisiae, Neurospora sitophila, Actinidia deliciosa, Actinidia chinensis, Marinobacter aquaeolei, Saccharomycopsis fibuligera, Malus x domestica, Solanum pennellii, or Solanum lycopersicum.
3. The genetically modified yeast cell according to claim 1 or 2, wherein the enzyme having AAT activity comprises a sequence having at least 90% sequence identity with the amino acid sequence represented by SEQ ID NO: 2 to 4 or 12 to 22.
4. 4. The genetically modified yeast cell according to any one of claims 1 to 3, wherein the enzyme having AAT activity does not comprise the sequence of SEQ ID NO:
1.
5. 5. The genetically modified yeast cell according to any one of claims 1 to 4, wherein the enzyme having AAT activity comprises the sequence of SEQ ID NO:
20.
6. 6. The genetically modified yeast cell according to any one of claims 1 to 5, wherein the enzyme having AAT activity comprises at least one substitution mutation at a position corresponding to position A144 and / or A360 of SEQ ID NO:
1.
7. 7. The genetically modified yeast cell of claim 6, wherein the substitution mutation at the position corresponding to position A144 of SEQ ID NO:1 is a phenylalanine.
8. 8. The genetically modified yeast cell of claim 6 or 7, wherein the substitution mutation at the position corresponding to position A360 of SEQ ID NO:1 is isoleucine.
9. 9. The genetically modified yeast cell according to any one of claims 1 to 8, wherein the enzyme having AAT activity comprises at least one substitution mutation at a position corresponding to position A169 and / or A170 of SEQ ID NO:
19.
10. 10. The genetically modified yeast cell of claim 9, wherein the substitution mutation at the position corresponding to position A169 of SEQ ID NO: 19 is a glycine.
11. 11. The genetically modified yeast cell of claim 9 or 10, wherein the substitution mutation at the position corresponding to position A170 of SEQ ID NO: 19 is a phenylalanine.
12. 12. The genetically modified yeast cell of claim 1, wherein the enzyme having AAT activity comprises a substitution mutation at a position corresponding to position G150 of the wild-type MhWES2 amino acid sequence.
13. 13. The genetically modified yeast cell of claim 12, wherein the substitution mutation at the position corresponding to position G150 of the wild-type MhWES2 amino acid sequence is a phenylalanine.
14. A genetically modified yeast cell according to any one of claims 1 to 13, wherein the enzyme having FAS2 activity originates from Saccharomyces cerevisiae.
15. 15. The genetically modified yeast cell according to any one of claims 1 to 14, wherein the enzyme having FAS2 activity comprises a sequence having at least 90% sequence identity with the sequence of SEQ ID NO:
6.
16. 16. The genetically modified yeast cell of claim 15, wherein the enzyme having FAS2 activity does not comprise the sequence of SEQ ID NO:
5.
17. 17. The genetically modified yeast cell of claim 15 or 16, wherein the enzyme having FAS2 activity comprises a substitution mutation at a position corresponding to position 1250 of SEQ ID NO:
5.
18. 18. The genetically modified yeast cell of claim 17, wherein the substitution mutation at the position corresponding to position 1250 of SEQ ID NO:5 is a serine.
19. 19. The genetically modified yeast cell according to any one of claims 1 to 18, wherein the enzyme having HCS activity is derived from Cannabis sativa.
20. 20. The genetically modified yeast cell of claim 19, wherein the enzyme having HCS activity comprises a sequence having at least 90% sequence identity with the sequence of SEQ ID NO:
7.
21. 21. The genetically modified yeast cell of any one of claims 1 to 20, wherein the first promoter and / or the promoter operably linked to the gene encoding an enzyme having FAS2 activity is selected from the group consisting of pHEM13, pSPG1, pPRB1, pQCR10, pPGK1, pOLE1, pERG25, and pHHF2.
22. i) the first promoter is pHEM13 and the promoter operably linked to a gene encoding an enzyme having FAS2 activity is pSPG1; ii) the first promoter is pHEM13 and the promoter operably linked to a gene encoding an enzyme having FAS2 activity is pPRB1; iii) the first promoter is pQCR10 and the promoter operably linked to the gene encoding the enzyme having FAS2 activity is pPRB1; or iv) the first promoter is pPGK and the promoter operably linked to the gene encoding the enzyme having FAS2 activity is pPRB1; 22. The genetically modified yeast cell of claim 21.
23. 23. The genetically modified yeast cell of any one of claims 1 to 22, wherein the promoter operably linked to the gene encoding an enzyme having HCS activity is selected from the group consisting of pHEM13, pSPG1, pPRB1, pQCR10, pPGK1, pOLE1, pERG25, and pHHF2.
24. i) the first promoter is pHEM13, the promoter operably linked to the gene encoding the enzyme having FAS2 activity is pPRB1, and the promoter operably linked to the gene encoding the enzyme having HCS activity is pHEM13; ii) the first promoter is pQCR10, the promoter operably linked to the gene encoding the enzyme having FAS2 activity is pPRB1, and the promoter operably linked to the gene encoding the enzyme having HCS activity is pHEM13; or iii) the first promoter is pPGK1, the promoter operably linked to the gene encoding the enzyme having FAS2 activity is pPRB1, and the promoter operably linked to the gene encoding the enzyme having HCS activity is pERG25; 24. The genetically modified yeast cell of claim 23.
25. 25. The genetically modified yeast cell of any one of claims 1 to 24, wherein the cell is genetically modified to reduce expression of one or more endogenous AAT enzymes.
26. 26. The genetically modified yeast cell of claim 25, wherein the genetically modified yeast cell does not express endogenous EEB1, EHT1, and / or MGL2.
27. 27. The genetically modified yeast cell of any one of claims 1 to 26, wherein the genetically modified yeast cell is of the genus Saccharomyces.
28. 28. The genetically modified yeast cell of claim 27, wherein the genetically modified yeast cell is of the species Saccharomyces cerevisiae (S. cerevisiae).
29. 30. The genetically modified yeast cell of claim 28, wherein the yeast cell is S. cerevisiae California Ale Yeast strain WLP001, EC-1118, Elegance, Red Star Cote des Blancs, or Epernay II.
30. 28. The genetically modified yeast cell of claim 27, wherein the genetically modified yeast cell is of the species Saccharomyces pastorianus (S. pastorianus).
31. 31. The genetically modified yeast cell of any one of claims 1 to 30, wherein the growth rate of the genetically modified yeast cell is not substantially impaired compared to a wild-type yeast cell that does not comprise the first heterologous gene and the one or more additional genes.
32. 32. The genetically modified yeast cell of claim 31, wherein within one month of initiating fermentation, the genetically modified yeast cell fermentes an amount of fermentable sugars equivalent to the amount fermented by a wild-type yeast cell that does not contain the first heterologous gene and the one or more additional genes.
33. 33. The genetically modified yeast cell of claim 32, wherein within one month of initiating fermentation, the genetically modified yeast cell reduces the amount of fermentable sugars in the medium by at least 95%.
34. 34. The genetically modified yeast cell of any one of claims 1 to 33, wherein the genetically modified yeast cell comprises an endogenous gene encoding an enzyme having FAS2 activity.
35. 35. The genetically modified yeast cell according to any one of claims 1 to 34, wherein the one or more additional genes consist of a gene encoding an enzyme having FAS2 activity operably linked to a promoter.
36. 35. The genetically modified yeast cell of any one of claims 1 to 34, wherein the one or more additional genes consist of a gene encoding an enzyme having HCS activity operably linked to a promoter.
37. 35. The genetically modified yeast cell of any one of claims 1 to 34, wherein the one or more additional genes consist of a gene encoding an enzyme having FAS2 activity operably linked to a promoter, and a gene encoding an enzyme having HCS activity operably linked to a promoter.
38. Contacting the genetically modified yeast cell according to any one of claims 1 to 37 with a medium comprising at least one fermentable sugar.
1. A method for producing a fermentation product comprising: wherein the contacting is carried out during at least a first fermentation process to produce a fermentation product.
39. 39. The method of claim 38, wherein the at least one fermentable sugar is provided in at least one sugar source.
40. 40. The method of claim 38 or 39, wherein the fermentable sugar is glucose, fructose, sucrose, maltose, and / or maltotriose.
41. 41. The method of any one of claims 38 to 40, wherein the fermentation product comprises an increased level of at least one desired product compared to a fermentation product produced by an equivalent cell that does not express a gene encoding an AAT, FAS2, and / or HCS enzyme activity or that expresses a wild-type enzyme having AAT activity.
42. 42. The method of claim 41 , wherein the desired product is ethyl hexanoate.
43. 43. The method of any one of claims 38 to 42, wherein the fermentation product comprises a reduced level of at least one undesirable product compared to a fermentation product produced by an equivalent cell that does not express a gene encoding an AAT, FAS2, and / or HCS enzyme activity or that expresses a wild-type enzyme having AAT activity.
44. 44. The method of claim 43, wherein the at least one undesired product is hexanoic acid.
45. The method according to any one of claims 38 to 44, wherein the fermentation product is a fermented beverage.
46. 46. The method of claim 45, wherein the fermented beverage is beer, wine, sparkling wine (champagne), wine cooler, wine spritzer, hard seltzer, sake, mead, kombucha, or apple cider.
47. 47. The method of any one of claims 38 to 46, wherein the sugar source comprises wort, must, fruit juice, honey, rice starch, or a combination thereof.
48. 48. The method of claim 47, wherein the fruit juice is obtained from at least one fruit selected from the group consisting of grapes, apples, blueberries, blackberries, raspberries, currants, strawberries, cherries, pears, peaches, nectarines, oranges, pineapples, mangoes, and passion fruit.
49. The sugar source is malt; and The method further comprises producing the medium, wherein producing the medium comprises: (a) contacting a plurality of grains with water; and (b) The production of wort by boiling or steeping water and grains.
48. The method of claim 47, comprising:
50. 50. The method of claim 49, further comprising adding at least one hop variety to the wort to produce a hopped wort.
51. The method of any one of claims 38 to 50, further comprising adding at least one hop variety to the medium.
52. The sugar source is must, and The method further comprises producing the medium, wherein producing the medium comprises: The production of must by squeezing multiple fruits 48. The method of claim 47, comprising:
53. 53. The method of claim 52, further comprising removing solid fruit material from the must to produce juice.
54. 54. The method of any one of claims 38 to 53, further comprising at least one additional fermentation process.
55. 55. The method of any one of claims 38 to 54, further comprising carbonating the fermentation product.
56. A fermentation product produced, obtained or obtainable by the method according to any one of claims 38 to 55.
57. 57. The fermentation product of claim 56, wherein the fermentation product contains at least 200 μg / L of ethyl hexanoate.
58. 58. The fermentation product of claim 56 or 57, wherein the fermentation product contains less than 10 mg / L hexanoic acid.
59. 1. A method for producing a composition comprising ethanol, the method comprising: Contacting the genetically modified yeast cell according to any one of claims 1 to 37 with a medium comprising at least one fermentable sugar. wherein such contacting is performed during at least a first fermentation process to produce a composition comprising ethanol.
60. 60. The method of claim 59, wherein the at least one fermentable sugar is provided in at least one sugar source.
61. 61. The method of claim 59 or 60, wherein the fermentable sugar is glucose, fructose, sucrose, maltose, and / or maltotriose.
62. 62. The method of any one of claims 59-61, wherein the composition comprising ethanol comprises an increased level of at least one desired product compared to a composition comprising ethanol produced by a comparable cell that does not express genes encoding AAT, FAS2, and / or HCS enzyme activity or that expresses a wild-type enzyme having AAT activity.
63. The method of claims 59 to 62, wherein the desired product is ethyl hexanoate.
64. 64. The method of any one of claims 59-63, wherein the composition comprising ethanol comprises a reduced level of at least one undesirable product compared to a composition comprising ethanol produced by a comparable cell that does not express a gene encoding an AAT, FAS2, and / or HCS enzyme activity or that expresses a wild-type enzyme having AAT activity.
65. 65. The method of claim 64, wherein the at least one undesired product is hexanoic acid.
66. 66. The method of any one of claims 59 to 65, wherein the composition comprising ethanol is a fermented beverage.
67. 67. The method of claim 66, wherein the fermented beverage is beer, wine, sparkling wine (champagne), wine cooler, wine spritzer, hard seltzer, sake, mead, kombucha, or apple cider.
68. 68. The method of any one of claims 59 to 67, wherein the sugar source comprises wort, must, fruit juice, honey, rice starch, or a combination thereof.
69. 69. The method of claim 68, wherein the fruit juice is obtained from at least one fruit selected from the group consisting of grapes, apples, blueberries, blackberries, raspberries, currants, strawberries, cherries, pears, peaches, nectarines, oranges, pineapples, mangoes, and passion fruit.
70. The sugar source is malt; and The method further comprises producing the medium, wherein producing the medium comprises: (a) contacting a plurality of grains with water; and (b) The production of wort by boiling or steeping water and grains.
69. The method of claim 68, comprising:
71. 71. The method of claim 70, further comprising adding at least one hop variety to the wort to produce a hopped wort.
72. 72. The method of any one of claims 59 to 71, further comprising adding at least one hop variety to the medium.
73. The sugar source is must, and 69. The method of claim 68, wherein the method further comprises producing a medium, and wherein producing the medium comprises pressing the plurality of fruits to produce a must.
74. 74. The method of claim 73, further comprising removing solid fruit material from the must to produce juice.
75. 75. The method of any one of claims 59 to 74, further comprising at least one additional fermentation process.
76. 76. The method of any one of claims 59 to 75, further comprising carbonating a composition comprising ethanol.
77. 77. A composition comprising ethanol, wherein the composition is produced, obtained or obtainable by a method according to any one of claims 59 to 76.
78. 78. The composition of claim 77, wherein the composition comprises at least 200 μg / L of ethyl hexanoate.
79. 80. The composition of claim 77 or 78, wherein the composition comprises less than 10 mg / L hexanoic acid.
80. 38. A composition comprising ethanol, the composition comprising at least 200 μg / L ethyl hexanoate, less than 10 mg / L hexanoic acid, and the genetically modified yeast cell of any one of claims 1-37.
